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1 Abstract 
Diseases of the kidney filtration barrier are a major cause of renal failure and 
cardiovascular mortality. Podocytes maintain the glomerular filtration barrier and 
podocyte dysfunction leads to the development of glomerulosclerosis, i.e. glomerular 
scarring. Mutations in the SPFH domain-containing protein podocin, which is 
localized to the specialized cell-cell contact of podocytes, the slit diaphragm, can 
cause one of the most frequent glomerulopathies, FSGS. Podocin is one of the most 
extensively studied proteins in podocytes but nothing is known about other SPFH 
domain-containing proteins in podocytes so far. Since it has been speculated that 
mitochondrial dysfunction may contribute to podocyte injury in glomerular diseases 
this thesis work investigated the podocyte-specific function of a mitochondrially 
localized SPFH domain-containing protein, prohibitin-2 (PHB2). PHB2 is important for 
maintaining normal cristae structures and proper mitochondrial function. 
Podocyte-specific loss of PHB2 in mice resulted in the development of progressive 
albuminuria, glomerulosclerosis and endstage renal failure. Unexpectedly, 
immunofluorescence stainings and immunogold labeling detected PHB2 not only in 
mitochondria but also at the slit diaphragm. PHB2 co-precipitated with podocin, 
thereby suggesting an extramitochondrial role of PHB2 at the slit diaphragm. 
Supporting these results, the ortholog of PHB2 in C. elegans was also not restricted 
to mitochondria but associated with a mechanosensory complex containing the 
podocin ortholog MEC-2. Given the high similarity of the mechanosensory complex in 
worms and the slit diaphragm complex in mammals, functional assays of the 
mechanosensor were performed. Knockdown of phb-2 as well as loss of mec-2 in the 
mechanosensitive neurons resulted in impaired touch sensitivity, showing a 
functional impact of PHB2 on this conserved protein-lipid supercomplex.  
Furthermore, it was shown before that loss of insulin signaling increases lifespan of 
Phb2/phb-2-deficient yeast and worms. Therefore, apart from the findings at the slit 
diaphragm, the impact of PHB2 on podocyte metabolism was investigated. 
Phb2-deficiency in podocytes led to increased activity of mTORC1. Treatment of 
these animals with rapamycin or additional knockout of the insulin and IGF-1 receptor 
prolonged survival despite progressive albuminuria. Collectively, these data indicate 
that loss of PHB2 at the slit diaphragm resulted in the development of albuminuria but 
loss of podocytes was dependent on metabolic dysregulation.  
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2 Zusammenfassung 
Erkrankungen des Nierenfilters stellen eine der Hauptursachen für Nierenversagen 
und kardiovaskuläre Mortalität dar. Podozyten sind ein wichtiger Bestandteil der 
glomerulären Filtrationsbarriere und eine podozytäre Dysfunktion führt zur Proteinurie 
und Glomerulosklerose, d.h. glomerulären Vernarbung. Mutationen in dem SPFH-
Domänen-Protein Podocin, das an den spezialisierten Zell-Zell-Kontakt von 
Podozyten, die Schlitzmembran, lokalisiert, führen zu einer der häufigsten 
Glomerulopathien, der FSGS. Podocin gehört zu den am meisten untersuchten 
Proteinen im Podozyten, jedoch ist über weitere SPFH-Domänen-Proteine in diesem 
Zelltyp bisher nichts bekannt. Da spekuliert wird, dass eine mitochondriale 
Dysfunktion zum Podozytenschaden in glomerulären Erkrankungen beitragen 
könnte, beschäftigt sich diese Doktorarbeit mit der podozyten-spezifischen Funktion 
eines mitochondrial-lokalisierten SPFH-Domänen-Proteins, Prohibitin-2 (PHB2). 
PHB2 ist unter anderem wichtig für den Aufbau und Erhalt der Cristae-Strukturen 
sowie normale mitochondriale Funktionen. 
Der Podozyten-spezifische Verlust von PHB2 führt in Mäusen zur Entwicklung einer 
fortschreitenden Albuminurie, Glomerulosklerose und terminalem Nierenversagen. 
Dabei konnten Immunfluoreszenz- und Immunogoldfärbungen PHB2 nicht nur in 
Mitochondrien, sondern auch an der Schlitzmembran nachweisen. PHB2 
ko-präzipitierte mit Podocin, was eine extramitochondriale Rolle von PHB2 an der 
Schlitzmembran nahelegt. Darüber hinaus fand sich das PHB2-Ortholog in 
C. elegans nicht nur in Mitochondrien, sondern auch im mechanosensorischen 
Komplex, der das Podocin-Ortholog MEC-2 enthält. In Anbetracht der hohen 
Vergleichbarkeit des mechanosensorischen Komplexes in Würmern und dem 
Schlitzmembrankomplex in Säugern wurden funktionelle Assays des 
Mechanosensors durchgeführt. Sowohl eine verringerte phb-2-Expression als auch 
der Verlust von mec-2 in den mechanosensitiven Neuronen führte zu einer 
verringerten Berührungssensitivität. Dies deutet auf einen funktionellen Einfluss von 
PHB2 auf diesen konservierten Protein-Lipid-Superkomplex hin. 
Ferner wurde bereits gezeigt, dass der Verlust des Insulinsignalweges die 
Lebensspanne von Phb2/phb-2-defizienten Hefen und Würmern verlängert. Deshalb 
wurde – unabhängig von den Erkenntnissen an der Schlitzmembran – der Einfluss 
von PHB2 auf den Metabolismus von Podozyten untersucht. Eine Phb2-Defizienz in 
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Podozyten führt zu einer erhöhten Aktivierung von mTORC1. Die Behandlung dieser 
Tiere mit Rapamycin sowie der zusätzliche Verlust des Insulin- und IGF-1-Rezeptors 
verlängerten das Überleben der Tiere trotz fortschreitender Albuminurie. 
Zusammengefasst bedeutet dies, dass das Fehlen von PHB2 an der Schlitzmembran 
zur Entstehung der Albuminurie beiträgt, während der Verlust der Podozyten 
vermutlich auf eine metabolische Dysregulierung in Folge einer Dysregulation des 
Insulin/mTOR-Signalweges zurückzuführen ist. 
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3 Introduction 
 
3.1 Podocytes in glomerular diseases 
Glomerular diseases represent a major cause of chronic kidney disease (CKD) 
affecting more than 5% of all human beings world-wide. They share common 
features e.g. loss of plasma proteins into the urine (albuminuria and proteinuria) and 
glomerular degeneration, fibrosis and scarring (glomerulosclerosis). Both, proteinuria 
and chronic kidney disease are independently associated with increased risk for 
endstage renal failure and cardiovascular diseases [1,2]. 
Each human kidney contains about one million small filtering units, the glomeruli. 
Blood plasma has to pass the glomerular filtration barrier, which is responsible for the 
size- and charge-selectivity of the kidney filter and produces an almost protein-free 
ultrafiltrate. The glomerular filtration barrier is composed of three layers: fenestrated 
endothelium, glomerular basement membrane and podocytes [3,4] (Figure 1). 
 
 
Figure 1: The three layers of the glomerular filtration barrier 
The glomerular filtration barrier consists of three layers that are important for filtration 
of blood plasma: podocytes with their foot processes (FP), glomerular basement 
membrane (GBM) and fenestrated endothelial cells (EC). 
 
Podocytes are the visceral epithelial cells of the kidney glomerulus. They elaborate 
long interdigitated foot processes that completely enwrap the glomerular capillaries in 
a complex network. The intercellular slit inbetween neighbouring foot processes is 
bridged by a continous membrane-like cell junction, the slit diaphragm [3].  
Genetic studies of the last decade showed that glomerular podocytes are essential 
for the function and integrity of the kidney filter and critically involved in the 
development of proteinuria [5,6]. Podocyte injury in renal diseases is reflected by foot 
process effacement, i.e. retraction of the membrane extensions, and ultimately cell 
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death. Since podocytes are terminally differentiated epithelial cells, podocyte loss 
inevitably leads to a reduced cell number which is negatively correlated with renal 
survival [7,8]. Not only inflammation, toxins and mechanical stress but also gene 
mutations can be the cause of podocyte injury [9]. Numerous studies within the last 
decades on hereditary glomerular diseases identified mutations in genes encoding 
for proteins that localize to the podocyte slit diaphragm, e.g. cytoskeleton-associated 
CD2AP [10,11], the immunoglobulin family member nephrin [12,13], the ion channel 
TRPC6 [14,15] and the SPFH domain-containing protein podocin [16–19]. 
 
3.2 SPFH domain-containing protein family 
3.2.1 General information 
The SPFH domain-containing protein family was named after the initials of the 
proteins in this family: stomatins, prohibitins, flotillins and HflK/C. Initially, the SPFH 
domain was identified in stomatins and database searches revealed that other 
proteins like prohibitins contain a strikingly similar domain (also called PHB domain) 
[20]. The SPFH domain is not only conserved among different proteins but also 
across species [20–22]. Among others, erlins and podocin as well as the podocin 
homolog MEC-2 in C. elegans are prominent members of this protein family 
[3,23,24]. Many SPFH domain-containing proteins form homo-oligomers by 
interacting via the SPFH domain [25–27]. However, also hetero-oligomers exist as 
shown for the complexes that are made up of prohibitin-1 and prohibitin-2 [28]. Most 
of the SPFH domain-containing proteins have been shown to be enriched in 
detergent resistant membranes (DRM) [21,29–34], but so far no common function 
could be attributed to all members of this family. The SPFH domain is suggested to 
be either a protein-binding or a lipid-binding motif but no protein-binding partner was 
identified which is universal for all family members [21]. Since many of the SPFH 
domain-containing proteins are associated with DRMs - which are defined by their 
specific lipid composition [35] – it seems to be very probable that this domain is 
necessary for specific protein-lipid interactions [21]. This has already been shown for 
podocin/MEC-2, which bind to cholesterol in the plasma membrane [24], but still 
needs to be proven for other members of the SPFH domain-containing protein family.  
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3.2.2 Podocin 
Podocin is an integral membrane protein encoded by NPHS2. It consists of one 
transmembrane domain and a carboxy-terminal cytoplasmic tail. The protein 
sequence shows strong homology to the corresponding regions of stomatin family 
proteins [16,36]. During glomerular development podocin is expressed in 
“mesonephric podocytes from the S-shaped body and, later, in the metanephric 
kidney, in the future podocytes at the late S-shaped body stage” [36]. In the mature 
kidney podocin expression is exclusively detectable in podocytes where the protein is 
localized at the slit diaphragm [36]. NPHS2 mutations are involved in the 
development of a familial form of early-onset steroid-resistant nephrotic syndrome 
progressing towards focal segmental glomerulosclerosis (FSGS) as well as in 
sporadic cases of the disease and late-onset inherited FSGS [16,17,37–41]. 
NPHS2-knockout mice develop normally but show massive proteinuria shortly after 
birth due to severe podocyte foot process effacement resulting in end-stage renal 
failure and premature death within the first weeks of life [18]. 
In the nematode C. elegans MEC-2 - the worm homolog of podocin – is located along 
regular touch punctae along the six touch receptor neuron processes. Here, MEC-2 
is part of a multiprotein-channel complex that is needed to convert mechanical stimuli 
into electrical signals [42,43]. MEC-2 regulates the function of MEC-4/MEC-10, two 
degenerin/epithelial Na+ channels (DEG/ENaC) that transduce gentle body touch 
sensation [42,44,45]. In mammals, the ion channel TRPC6 - a member of the 
transient receptor potential (TRP) superfamily - is associated with the slit diaphragm 
[14,15], where it interacts with other slit diaphragm proteins [14,24]. TRP channels 
are mechanically gated ion channels [46] which can be regulated by podocin [24]. 
This renders the slit diaphragm a possible mechanosensitive structure which can 
more easily be studied in C. elegans [47]. 
3.2.3 Prohibitins 
Prohibitin-1 (PHB1) and prohibitin-2 (PHB2) are two closely related proteins that 
reside within the inner mitochondrial membrane. Unconventional sorting sequences 
target both proteins to mitochondria, where they are inserted into the inner 
membrane by TIM23-translocase activity. Protein structure analysis revealed that 
they are anchored to the membrane by a hydrophobic stretch located at the amino 
terminal end while the large carboxy terminal end, which consists of a PHB-domain 
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and a coiled coil domain, is exposed to the intermembrane space [28,48]. PHB1 and 
PHB2 directly interact by forming multimeric ring complexes (Figure 2) and stabilize 
each other [28,49,50].  
 
 
Figure 2: Multimeric ring complexes of prohibitins 
Prohibitin-1 and prohibitin-2 are assembled in heteromeric ring structures and 
thereby stabilize each other. (Figure adapted from Osman et al., 2009 [51]) 
 
Prohibitins are involved in numerous functions within the cell. Not only are they 
needed for the maintenance of the mitochondrial membrane and cristae structure but 
also serve a scaffolding function during biogenesis of oxidative phosphorylation 
system (OXPHOS) complexes [52,53]. Moreover, prohibitins seem to be important for 
the regulation of apoptosis [53–56] and can reside within the nucleus where they 
modulate transcriptional activity [54,57–60]. Nevertheless, it is generally conceived 
that the majority of prohibitins is localized within the mitochondrial compartment. 
Prohibitins are upregulated in various types of cancers e.g. breast cancer [61] and 
gastric cancer [62] but seem to have protective roles in many normal tissues. For 
example PHBs are required to prevent ethanol-mediated damage of pancreatic 
β-cells [55,63] and can stop the progression of TGF-β1-induced renal 
tubulointerstitial lesions [64]. 
In 2008, Merkwirth et al. [53] showed that cellular depletion of PHB2 in mouse 
embryonic fibroblasts (MEFs) led to decreased levels of PHB1, markedly reduced 
proliferation and an increased susceptibility to apoptotic stimuli. The cells exhibited 
disorganized and swollen mitochondrial cristae structures. However, mitochondrial 
membrane potential and enzymatic activities of respiratory complexes were 
unaffected. An impaired processing of the dynamin-like GTPase OPA1 (optic 
atrophy 1) was identified as the primary cellular defect in the absence of prohibitins 
[53]. Correct cleavage of OPA1 into five different short and long isoforms is required 
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for mitochondrial fusion, thereby promoting cristae maintenance and remodeling [65–
68]. 
Universal knockout of Phb2 in a mouse model resulted in no viable offspring [53,59]. 
Recently, loss of regular mitochondrial cristae structures and impaired OPA1 
cleavage was demonstrated in a neuronal-specific Phb2-knockout mouse model 
in vivo [69], thereby confirming the phenotype that was observed in isolated 
Phb2-deficient MEFs [53]. Phb2-deficiency in C. elegans led to increased fat 
utilization, increased mitochondrial proliferation, consequent cellular damage and an 
ultimately reduced lifespan. However, loss of PHB-2 increased lifespan of already 
long-lived insulin receptor/daf-2-mutant worms and partially restored the metabolic 
defects observed in Phb2-deficient worms, thereby linking prohibitins to the metabolic 
signaling pathways [70]. Furthermore, a recent study in prohibitin-deficient yeast cells 
revealed that loss of prohibitins leads to increased mitochondrial proteotoxic stress, 
which activates the mitochondrial untranslated protein response (mtUPR). This effect 
can be reversed under dietary restriction i.e. less nutrient signaling, probably via 
decreasing cytoplasmic mRNA translation [71]. In conclusion, experiments in yeast 
and worm link PHB2 to the action of insulin. 
 
3.3 Regulation of metabolism by mTOR signaling 
3.3.1 The mTOR pathway 
The nutrient-sensing Ser/Thr kinase mammalian target of rapamycin (mTOR) is one 
of the central regulators for metabolism in cells and organisms. mTOR can assemble 
with other proteins into two distinct complexes, mTORC1 and mTORC2. In the 
rapamycin-sensitive mTORC1 complex mTOR associates with raptor and regulates 
temporal aspects of cell growth whereas the rapamycin-insensitive mTORC2 
complex contains rictor and controls spatial aspects of cell growth [72–76]. To exert 
its function mTORC1 signaling increases e.g. transcription and protein synthesis but 
inhibits autophagy. The mTORC2 complex mainly regulates actin organization [77].  
The activity of mTOR complexes is regulated by different upstream signals that either 
downregulate or upregulate mTOR activity. On the one hand, stress signals like 
hypoxia as well as low cellular energy states downregulate mTOR signaling to arrest 
cell growth [78–81]. Hypoxia increases the HIF1-mediated expression of REDD, 
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which activates the tuberous sclerosis complex consisting of the heterodimer TSC1 
and TSC2. TSC1-TSC2 negatively regulate mTOR activity via Rheb [82–84]. Low 
cellular energy leads to activation of AMP-activated protein kinase (AMPK), which 
activates TSC2, resulting in the inhibition of mTORC1 activity [80,85]. On the other 
hand, amino acids and growth factors increase mTOR signaling. So far, it is not clear 
how the amino acid status is communicated to the mTOR complex, but one 
hypothesis is that it works independent of the TSC complex by direct activation of 
Rheb, which in turn activates the mTOR complex. Two of the most important 
activators of the mTOR pathway are the growth factors insulin and insulin-like growth 
factor 1 (IGF-1). Each binds to its specific receptor at the plasma membrane and 
inhibits TSC1-TSC2 via the phosphoinositide 3-kinase (PI3K) pathway, thereby 
promoting activation of mTOR and cell growth [86–90] (Figure 3).  
Two of the best understood downstream mediators of mTOR function are the 
ribosomal S6 kinase S6K1 and the eukaryotic initiation factor 4-binding protein 
4E-BP1. mTORC1 activation leads to phosphorylation of S6K1, which then 
phosphorylates the 40S ribosomal protein S6, ultimately leading to translation of 
proteins necessary for ribosomal biogenesis [91]. Moreover, mTORC1 signaling 
promotes phosphorylation of 4E-BP1, leading to the release of eukaryotic initiation 
factor 4E (eIF4E) [91,92]. Both downstream effectors initiate protein translation and 
can be used as in vitro and in vivo readout for mTORC1 activity [93].  
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Figure 3: mTOR pathway 
The mTOR pathway can be activated by different signals. Insulin and IGF-1 are 
acting via growth factor receptors and the PI3K pathway to inhibit the TSC1-TSC2 
complex. Hypoxia mediates inhibition of TSC1-TSC2 via increasing expression of 
REDD. Low energy states are sensed by AMPK, which also acts on the TSC 
complex. Amino acids most likely act downstream of the TSC complex by activating 
Rheb. The two mTOR-complexes contain either mTOR and raptor (mTORC1) or 
mTOR and rictor (mTORC2). The mTORC1 complex controls temporal aspects of 
cell growth by regulation of e.g. translation, transcription and autophagy whereas the 
mTORC2 complex regulates spatial aspects of cell growth via actin organization. 
(Figure adapted from Wullschleger et al., 2006 [77]) 
 
3.3.2 Role of mTOR signaling in podocytes 
Several studies revealed that patients with glomerular diseases like FSGS [94] and 
diabetic nephropathy [95–99] may benefit from mTORC1 inhibition by rapamycin 
treatment. However, rapamycin treatment also frequently leads to the development of 
de novo proteinuria, especially in transplant patients [100–102]. To further 
understand the role of mTOR in podocytes Gödel et al. [95] generated a podocyte-
specific raptor-knockout mouse to specifically abrogate function of the mTORC1 
complex. These mice developed albuminuria at the age of four weeks and later 
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displayed with glomerulosclerosis, resulting in an increased mortality rate after eight 
month of age. By using an inducible mouse model they also showed that mTORC1 
function is not only important for the development but also for the maintenance of the 
glomerulus during adulthood. Ablation of mTORC2 function by podocyte-specific 
deletion of rictor did not lead to any overt phenotype under normal conditions, but 
these mice developed albuminuria when they were exposed to stress cues. However, 
a combination of raptor- and rictor-knockout led to a much faster progressing and 
more severe phenotype compared to the knockout of raptor alone [95]. In line with 
these findings, podocyte-specific depletion of the insulin receptor led to the 
development of proteinuria and first subtle changes in foot process structures at the 
age of five weeks. Histologically, these mice showed features of diabetic nephropathy 
[103]. Another study used a podocyte-specific TSC1-knockout mouse, thereby 
increasing mTORC1 activity. These mice developed albuminuria already at the age 
of two weeks and foot process effacement at four weeks of age. In addition, this 
phenotype was inducible in adult animals as well and the effects could be reversed 
by treatment with rapamycin [104]. These studies clearly demonstrate that a balance 
in mTORC1 activity is crucial for a healthy glomerular metabolism, but further work is 
needed to better understand the effects of different mTOR activity states in 
glomerular health and disease [105]. 
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4 Thesis aims 
The SPFH domain-containing protein podocin, a component of the protein-lipid 
supercomplex at the slit diaphragm of podocytes, is one of the best studied proteins 
in podocyte biology. Mutations in NPHS2, the gene encoding for podocin, are 
causing frequent glomerulopathies in humans. So far, little is known about the role of 
other SPFH domain-containing proteins in podocytes. Therefore, this PhD work 
investigated the role of prohibitin-2, another SPFH domain-containing protein with 
primarily mitochondrial function, in podocytes. Furthermore, recent reports from 
worms and yeast suggest a link between PHB2 and insulin signaling [70,71]. Since 
mTOR activity downstream of insulin signaling seems to be dysregulated in 
glomerulosclerosis [95,104,105], the connection between PHB2 and insulin/mTOR 
signaling was explored further. 
Therefore, the major aims for this thesis were: 
 
1. Generation and characterization of podocyte-specific Phb2-knockout mice 
Conditional Phb2 flox/flox mice were mated to podocyte-specific Cre mice 
(NPHS2.cre mice) to generate podocyte-specific Phb2-knockout mice 
(Phb2pko mice). The development of glomerular disease in these mice was 
analyzed at day 14, 21 and 28 after birth by measuring urinary albumin-to-
creatinine ratio with a combination of an ELISA and a colorimetric assay. 
Moreover, PAS staining, specific immunohistochemistry and electron 
microscopy were used to further characterize these mice. 
 
2. Determination of the localization of PHB2 in podocytes and investigation of 
a possible interaction with podocin 
To assess localization of PHB2 in podocytes two different techniques, 
immunofluorescence and immunogold labeling, were applied. To analyze a 
possible interaction with podocin co-immunoprecipitation experiments were 
performed from overexpressed and endogenous samples. 
 
3. Analysis of a functional impact of PHB2 on the protein-lipid supercomplex 
Immunofluorescence stainings were used to confirm the conserved 
localization of PHB-2 to the protein-lipid supercomplex in C. elegans. Gentle 
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touch assays were used to investigate a functional role of PHB-2 in touch 
sensation. 
 
4. Analysis of an impact of the insulin and IGF-1 receptor on the development 
of glomerular disease in Phb2pko mice 
Conditional Phb2 flox/flox mice were mated to Insr flox/flox / Igf1r flox/flox mice 
and NPHS2.cre mice to generate Phb2pko/Insrpko/Igf1rpko mice. Lifespan of 
these animals was recorded and albuminuria at different time points assessed 
in coomassie gels. 
 
5. Determination of a role of mTOR activation in the development of 
glomerular disease in Phb2pko mice 
Kidney sections from Phb2pko were stained by specific immunohistochemistry 
for mTORC1 activity. Phb2pko mice were treated with the mTORC1 inhibitor 
rapamycin and albuminuria by means of a coomassie gel as well as survival 
was assessed. 
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5 Material and methods 
 
5.1 Material 
5.1.1 Chemicals, reagents and solutions 
Table 1. List of chemicals, reagents and solutions 
Chemicals/Reagents/Solutions Product  no. Provider 
2-Mercaptoethanol M3148 Sigma 
Agarose A9539-500G Sigma 
Ammonium persulfate (APS) A0834 Applichem 
Ammonium sulfate 3746 Carl Roth 
Ampicillin Sodium Salt K029 Carl Roth 
ANTI-FLAG® M2 Affinity Gel A2220 Sigma 
Bacto™ yeast extract 212750 BD Biosciences 
Blasticidin S ant-bl-1 InvivoGen 
Boric acid 100165 Merck 
Bovine Serum Albumin (BSA) A7030 Sigma 
Bovine Serum Albumin (BSA), 10 mg/ml B9001 New England 
BioLabs 
Bovine Serum Albumin (BSA), fraction V 1066 Gerbu 
Bromphenol Blue A512 Carl Roth 
Cacodylic acid sodium salt trihydrate 5169 Carl Roth 
Calcium chloride dihydrate HN04 Carl Roth 
Cholesterol C8667 Sigma 
Citric acid monohydrate 27490 Sigma 
Collagen I, bovine A1064401 Invitrogen 
Collagenase Type 1A C9891 Sigma 
Coomassie brilliant blue G-250 161-0406 BioRad 
Coumeric Acid C9008 Sigma 
D(+)-Glucose monohydrate 1040740 Merck 
DAB substrate (10x) 1855920 Thermo Scientific 
Deoxyribonuclease I, bovine (DNase) D5319 Sigma 
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Chemicals/Reagents/Solutions Product  no. Provider 
Deoxyribonucleotide triphosphate (dNTP)-mix 200415 Stratagene 
Dimethyl sulfoxide (DMSO) Hybri-Max D2650 Sigma 
Dithiothreitol (DTT) 6908 Carl Roth 
Doxycycline hyclate A2951 Applichem 
Dulbecco’s Modified Eagle Medium (DMEM) D6429 Sigma 
Ethanol 96% + 1% Methyl ethyl ketone WAL641.5000 Th.Geyer Group 
Ethanol 99% + 1% Methyl ethyl ketone A5007 Applichem 
Ethanol absolut 9065 Carl Roth 
Ethidiumbromide solution (1%) 2218 Carl Roth 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
E3889 Sigma 
Ethylenediaminetetraacetic acid disodium salt 
dihydrate (EDTA) 
E5134 Sigma 
Fetal Bovine Serum (FBS) S 0115 Biochrom AG 
Formaldehyde solution 37% 2137.1011 Th.Geyer Group 
Freund's adjuvant, complete F5581 Sigma 
Freund's adjuvant, incomplete F5506 Sigma 
GeneRuler 1kb DNA Ladder SM0311 Fermentas 
GeneRuler 50bp DNA Ladder SM0373 Fermentas 
Glycerol 3783 Carl Roth 
Glycine 3908 Carl Roth 
HAT supplement 100x 21060-017 Gibco 
Heparin-Rotexmedica 3862340 Rotexmedica 
HEPES Buffer 1M H0887 Sigma 
Histo-Clear 905006 Biozym 
Histomount HS-103 National 
Diagnostics 
Hydrochlorid acid 2 N T134 Carl Roth 
Hydrogen Peroxide 30% 107209 Merck 
Igepal® CA-630 I8896 Sigma 
Imidazole X998 Carl Roth 
Material and methods 
16 
 
Chemicals/Reagents/Solutions Product  no. Provider 
Incidin Plus 3011520 Ecolab 
Interferon gamma, murine 1476960100 provitro 
Isopropanol 5752.3 Carl Roth 
Isopropyl-thio-β-d-galactoside (IPTG) A1800 Applichem 
Kanamycin sulfate K4000 Sigma 
Ketavet® 100 mg/ml   Pfizer 
LB-Agar X965 Carl Roth 
LB-Medium X964 Carl Roth 
L-Glutamine 200mM 25030-081 Gibco 
Lipofectamine-2000 11668-027 Invitrogen 
Loading Dye Solution (6X) R0611 Thermo Scientific 
Luminol 9253 Fluka 
Lysozyme A3711 Applichem 
Magnesium chloride hexahydrate 105833 Merck 
Magnesium sulfate heptahydrate P027 Carl Roth 
Mayer's hematoxylin MHS16 Sigma 
MEM non-essential amino acids (MEM NEAA) 
100x 11140-050 
Gibco 
Methanol  4627 Carl Roth 
MitoTracker® Red FM M22425 Invitrogen 
N,N,N´,N´-tetramethylethylenediamine 
(TEMED) 
2367 Carl  Roth 
Ni-NTA agarose 30210 Qiagen 
NEBuffer 3 B7003 New England 
BioLabs 
Ni-NTA agarose R901-01 Qiagen 
Normal Donkey Serum 017-000-121 Dianova 
Opti-MEM® 31985-047 Invitrogen 
Osmium tetroxide 8371 Carl Roth 
PageRuler Plus Prestained Protein Ladder 26620 Fermentas 
Paraformaldehyde (PFA) P6148 Sigma 
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Chemicals/Reagents/Solutions Product  no. Provider 
Passive Lysis Buffer 5x E1941 Promega 
Penicillin-Streptomycin 10,000 U/mL 15140-122 Gibco 
Peptone from casein, enzymatic digest 82393 Sigma 
Periodic acid 99% 3257 Carl Roth 
Phenylmethylsulfonyl fluoride (PMSF) P7626 Sigma 
Phosphoric acid 85% 79617 Sigma 
PIPES disodium salt P3768   
Polyacrylamide T802 Carl Roth 
Polyethylenglykol 400 0144 Carl Roth 
Ponceau S P7170 Sigma 
Potassium chloride 6781 Carl Roth 
Potassium dihydrogen phosphate  P-018 Carl Roth 
ProLong Gold antifade reagent with DAPI P-36931 Invitrogen 
Protein A Sepharose  10-1041 Invitrogen 
Protein G Sepharose  GEHE17-
0618-01 
VWR 
Proteinase K 82456 Sigma 
Pure acetic acid 99% - 100%  7332 Carl Roth 
Puromycin ant-pr-1 InvivoGen 
Qiazol 79306 Qiagen 
Rapamycin R-5000 LC Labs 
RNase-free water Ultra Pure 10977-035 Invitrogen 
Rompun® 2%   Bayer HealthCare 
RPMI-1640 medium 31870025 Gibco 
RPMI-1640 medium R8758 Sigma 
Schiff's reagent 109033 Merck 
Sodim citrate dihydrate 194868 MP Biomedicals 
Sodium acetate 6268 Merck 
Sodium azide S2002 Sigma 
Sodium chloride  3957 Carl Roth 
Sodium chloride solution 0,9%, isotonic 3563293 AlleMan Pharma 
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Chemicals/Reagents/Solutions Product  no. Provider 
Sodium deoxycholate D6750 Sigma 
Sodium dodecyl sulfate (SDS) pellets CN30 Carl Roth 
Sodium fluoride S-1504 Sigma 
Sodium hydrogen carbonate 106329 Merck 
Sodium hydroxide 402 J.T. Baker 
Sodium hydroxide solution 2 N T135 Carl Roth 
Sodium hypochlorite solution 12% 9026 Carl Roth 
Sodium orthovanadate S6508 Sigma 
Sodium pyruvate 100 mM 11360-070 Gibco 
Sodium pyruvate 100 mM S8636 Sigma 
Sodium(di-) hydrogen phosphate heptahydrate 106574 Merck 
Sodium(tetra-) diphosphate decahydrate 106591 Merck 
Spectinomycin dihydrochloride pentahydrate 567570 Merck 
Spermidine HCl S2501 Sigma 
TE buffer 60191 Invitrogen 
Tetramethylbenzidine (TMB) T2885 Sigma 
Tissue-Tek® O.C.T.™ compound 4583 Sakura 
Tris Hydrochlorid (HCl) 9090 Carl Roth 
Triton X-100 108603 Merck 
Trizma Base T1503 Sigma 
Trypsin-EDTA Solution (1x) T3924 Sigma 
Tryptone 1010817 MP Biomedicals 
Tween®20 3472 Caesar&Lorentz 
Tween®80 9139 Carl Roth 
Uranyl acetate 19481 Ted Pella Inc. 
Uranyl acetate dihydrate 73943 Sigma 
Vectastain® R.T.U. Elite™ ABC reagent PK-7100 
Vector 
Laboratories 
Zeocin ant-zn-1 InvivoGen 
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5.1.2 Assays/Kits 
Table 2. List of assays and kits 
Assay/Kit Product no. Provider 
Avidin/Biotin Blocking Kit SP-2001 Vector 
Laboratories 
BCA Protein Assay Kit 
23227 
Pierce/Thermo 
Scientific 
Big Dye® Terminator v3.1 Cycle Sequencing 
Kit 
4337455 Applied 
Biosystems 
Creatinie (urinary) Assay Kit 500701 Cayman 
DAB Substrate Kit 34002 Pierce/Thermo 
Scientific 
Direct-zol™ RNA Mini Prep Kit R2052 ZymoResearch 
Dual-Luciferase® Assay System E1910 Promega 
Epoxy Embedding Medium Kit 45359 Sigma 
GeneJet™ PCR Purification Kit K0702 Fermentas 
GeneJet™ Gel Extraction Kit K0692 Fermentas 
GeneJet™ Plasmid Miniprep Kit K0503 Fermentas 
GoTaq® Flexi DNA Polymerase M8301 Promega 
High Capacity cDNA Reverse Transcription  4368814 Applied 
Biosystems 
KOD Hot Start DNA Polymerase Kit 71086 Merck/Novagen 
Lowicryl® K4M Polar Kit 15923 Polysciences 
Mouse Albumin ELISA Kit 
E99-134 
Bethyl 
Laboratories 
NucleoBond® Xtra Midi Prep Kit  740410 Macherey-Nagel 
REDtaq® ReadyMix™ PCR Reaction Mix R2523 Sigma 
SuperSignal West Femto Chemiluminescent 
Substrate 34095 
Pierce/Thermo 
Scientific 
TaqMan® Universal Master Mix II 
4440040 Applied 
Biosystems 
Venor® GeM Mycoplasma Detection Kit 11-1050 Minerva Biolabs 
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Assay/Kit Product no. Provider 
Zenon® Tricolor Rabbit IgG Labeling Kit Z25360 Molecular Probes 
 
5.1.3 Buffers and solutions 
Table 3. Composition of buffers and solutions 
Buffer/Solution Composition 
Anesthesia 
  
   
6.8 ml 0.9% NaCl 
1 ml 100 mg/ml Ketavet® 
0.4 ml Rompun®  
Antibody Buffer A 
  
  
  
   
1% (w/v) BSA  
0.5% (v/v) Triton X-100 
0.05% (w/v) NaN3 
1 mM EDTA 
in 1x PBS  
Antibody Buffer B 
   
0.2% (w/v) BSA 
in Antibody Buffer A  
Base Solution 
   
  
0.025 N NaOH 
0.2 mM EDTA 
pH 12  
Blocking Solution 
  
   
5% (v/v) NDS 
0.1% (v/v) Triton-X100 
in 1x PBS  
Borate Buffer (40x) 
  
   
1 M boric acid 
500 mM NaOH 
pH 9.2  
Cell Culture Medium (HEK 293T) 
   
10% (v/v) FBS 
in DMEM  
Cell Culture Medium (Hybridoma) 
  
  
  
  
10% (v/v) FBS 
100 U/ml Penicillin-Streptomycin 
2 mM L-Glutamin 
0.5 mM Sodium pyruvate (Gibco) 
1x HAT supplement 
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Buffer/Solution Composition 
  
   
1x MEM NEAA 
in RPMI-1640 (Gibco) 
Cell Culture Medium (Mouse Podocytes) 
  
  
   
10% (v/v) FBS 
10 mM HEPES 
1 mM Sodium pyruvate (Sigma) 
in RPMI-1640 (Sigma)  
Cell Freezing Solution 
  
   
45% (v/v) FBS 
45% (v/v) DMEM or RPMI-1640 
10% (v/v) DMSO  
Citrate Buffer (10mM) 
  
   
1.26 mM Citric acid 
8.74 mM Sodium citrate 
pH 6 
Colloidal Coomassie Stock Solution 
  
  
  
755 mM (NH4)2SO4 
2.55% (v/v) Phosphoric acid 
0.1% (w/v) Coomassie brilliant blue G-
250  
Colloidal Coomassie Solution 
  
  
80% Colloidal Coomassie Stock 
Solution 
20% (v/v) Methanol  
Developer Solution 
  
  
   
48 mM Sodium acetate 
13.4% (v/v) H2O2 
98 µg/ml TMB 
pH 5.2  
ECL Detection Solution 
  
  
  
  
  
100 mM Tris  
1,25 mM Luminol  
0,2 mM Coumaric acid  
0,75% (v/v) H2O2  
pH 8.5 
  
Electron Microscopy Antibody Buffer 
  
  
1% BSA 
0.5% Tween®20 
0.1% Triton X-100 
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Buffer/Solution Composition 
   0.1 M Tris  
Electron Microscopy Fixation Buffer 
  
   
4% (v/v) PFA  
2% (v/v) Glutaraldehyde 
0.1 M Cacodylate  
Elution Buffer 
  
  
   
20 mM Tris 
150 mM NaCl 
300 mM Imidazole 
pH 8  
Fixing Solution for Worms 
   
1% (v/v) formaldehyde 
in 1x MRWB  
Fixing Solution for Coomassie 
   
25% (v/v) isopropanol 
10% (v/v) acetic acid  
HBSS (1x) 
   
1x HBSS solution A 
1x HBSS solution B  
HBSS Solution A (10x) 
  
  
  
  
  
   
5.4 mM KCl 
0.3 mM Na2HPO4 
0.4 mM KH2PO4 
4.2 mM NaHCO3 
137 mM NaCl 
5.6 mM D-glucose 
pH 7.4  
HBSS Solution B (10x) 
  
   
1.3 mM CaCl2 
0.5 mM MgCl2 
0.6 mM MgSO4  
HEBS (2X)  
  
  
  
   
50 mM HEPES  
280 mM NaCl  
10 mM KCl  
1.5 mM Na2HPO4  
pH 7.08  
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Buffer/Solution Composition 
His-Buffer 
  
  
   
50 mM Tris 
150 mM NaCl 
20 mM Imidazole 
pH 7.5  
IP Buffer 
  
  
  
  
   
20 mM Tris  
1% (v/v) Triton X-100  
50 mM NaCl  
15 mM Na4P2O7 
50 mM NaF 
pH 7.5  
Laemmli Sample Buffer (2X) 
  
  
  
  
   
100 mM Tris 
4% (w/v) SDS 
20% (v/v) Glycerol 
Bromphenol Blue 
100 mM DTT 
pH 6.8  
 Laemmli Sample Buffer (5X) 
  
  
  
  
   
250 mM Tris 
10% (w/v) SDS 
50% (v/v) Glycerol 
Bromphenol Blue 
250 mM DTT 
pH 6.8  
Ligation Buffer (10X)  
  
  
  
   
400 mM Tris 
100 mM MgCl2 
100 mM DTT 
5 mM ATP 
pH 7.8  
M9 Buffer 
  
  
   
22 mM KH2PO4 
42 mM Na2HPO4 
85.5 mM NaCl 
1 mM MgSO4  
Material and methods 
24 
 
Buffer/Solution Composition 
modified RIPA Buffer 
  
  
  
  
  
   
50 mM Tris-HCl 
1% (v/v) Igepal® CA-630 
0.25% (v/v) Sodium deoxycholate 
150 mM NaCl 
1 mM EDTA 
1 mM NaF 
pH 7.4  
modified Ruvkun's Witches Brew (MRWB) 
(2x) 
  
  
  
    
160 mM KCl 
40 mM NaCl 
20 mM EGTA 
10 mM Spermidine 
30 mM PIPES 
50% Methanol 
Nematode Growth Medium (NGM) 
  
  
  
  
  
   
51 mM NaCl 
59 mM Agar 
Peptone 
1 mM CaCl2 
1 mM Mg2SO4 
25 mM KH2PO4 
5 µg/ml Cholsterol  
Neutralization Solution 
   
40 mM Tris-HCl 
pH 5 
Phosphate Buffered Saline (PBS) 
  
  
   
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4  
PBS-Tween 
   
0.05% (w/w) Tween®20 
in 1x PBS  
Proteinase K Solution 
  
   
20 µg/ml Proteinase K 
50 mM Tris-HCl 
pH 7.8  
Material and methods 
25 
 
Buffer/Solution Composition 
Rapamycin Solution for injection 
  
  
   
0.3 mg/ml Rapamycin 
5% Tween®80 
5% PEG400 
sterile filtered with 0.22 µm filter  
Rapamycin Stock Solution 
   
6 mg/ml Rapamycin 
in 100% Ethanol  
Resolving Gel 
  
  
   
750 mM Tris 
10% (v/v) PAA 
0.2% (w/v) SDS 
pH 8.8  
Running Buffer 
  
   
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS  
Stacking Gel 
  
  
   
250 mM Tris 
5% (v/v) PAA 
0.2% (w/v) SDS 
pH 6.8  
Staining PBS 
  
   
1 mM CaCl2 
0,5 mM MgCl2 
in 1x PBS  
SOC Medium 
  
  
  
  
   
2% (w/v) Tryptone 
0.5% (w/v) Yeast Extract 
8.6 mM NaCl 
2.5 mM KCl  
20 mM MgSO4 
20 mM Glucose  
TAE (1X) 
  
  
   
40 mM Tris 
20 mM Acetic Acid 
1mM EDTA 
pH 8.5  
Material and methods 
26 
 
Buffer/Solution Composition 
TBS (1x) 
  
  
   
15 mM Tris-HCl 
4.5 mM Tris 
150 mM NaCl 
pH 7.6  
TBS-Tween (1x) 15 mM Tris-HCL 
4.5 mM Tris 
150 mM NaCl 
pH 7.6 
0.025% (v/v) Tween20 
Transfer Buffer 
  
   
25 mM Tris 
188 mM Glycine 
0.1% (w/v) SDS  
Tris-EDTA-Tween 10 mM Tris 
1 mM EDTA 
pH 9.0 
0.05% (v/v) Tween20 
Tris-Triton Buffer (TTB) 
  
  
   
100 mM Tris-HCl 
1% (v/v) Triton X-100 
1 mM EDTA 
pH 7.4  
Vehicle Solution for injection 
  
   
5% (v/v) Ethanol 
5% (v/v) Tween®80 
5% (v/v) PEG400  
Wash Buffer 
  
  
   
30 mM Tris 
300 mM NaCl 
0.3% (v/v) Tween20 
pH 7.5  
2x YTA 
  
  
85 mM NaCl 
16 g/l Tryptone 
10 g/l Yeast extract 
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5.1.4 Oligonucleotides 
Table 4. List of oligonucleotides used for cloning 
Cloning primers Sequence (5’  3’) 
ce phb-1 fp CAATGTTGATGGAGGTCAACG 
ce phb-1 rp GGTGACATTCTTGTTCTTGGC 
ce phb-2 ORF pEntry fp 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTGGCGAAA
CAAGGGCAAGAAGC 
ce phb-2 ORF pEntry rp 
GGGGACCACTTTGTACAAGAAAGCTGGGTAGCGTCTT
TTGTCGGTCAC 
ce pmec-17 fp 
GGGGACAACTTTGTATAGAAAAGTTGATTTTCTGAAATT
ACTATTA 
ce pmec-17 rp 
GGGGACTGCTTTTTTGTACAAACTTGTCATGATCGAAT
CGTCTCACAACT 
mPhb1 Mlu1 fp GCTGCCACGCGTACCATGGCTGCCAAAGTG 
mPhb1 Not1 rp ATGCACGCGGCCGCTCACTGGGGAAGCTGG 
mPhb2 Mlu1 fp GCTGCCACGCGTACCATGGCCCAGAACTTG 
mPhb2 Not1 rp ATGCACGCGGCCGCTCATTTCTTACCCTTAATG 
 
Table 5. List of oligonucleotides used for genotyping 
Genotyping primers  Sequence (5'  3') 
β-globin fp TGCTCACACAGGATAGAGAGGGCAGG 
β-globin rp GGCTGTCCAAGTGATTCAGGCCATCG  
Cre fp GGACATGTTCAGGGATCGCCAGGCG  
Cre rp GCATAACCAGTGAAACAGCATTGCTG  
Dicer fp CCTGACAGTGACGGTCCAAAG  
Dicer rp CATGACTCTTCAACTCAAACT  
iCreER(T2) fp TCAACATGCTGCACAGGAGAT  
iCreER(T2) rp ACCATAGATCAGGCGGTGGGT  
Igf1r fp TCCCTCAGGCTTCATCCGCAA  
Igf1r rp CTTCAGCTTTGCAGGTGCACG  
Insr fp GATGTGCACCCCATGTCTG  
Insr rp CTGAATAGCTGAGACCACAG  
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Genotyping primers  Sequence (5'  3') 
Phb2 fp ATCGTATTGGTGGCGTGCAGCA 
Phb2 rp1 CGAGGTCTGGCCCGAATGTCAT 
Phb2 rp2 AGGGAGGCTTGGTTTGAGGGGA 
 
Table 6. List of oligonucleotides for sequencing 
Sequencing primers Sequence (5’  3’) 
ce phb-2 ORF  
pos. 1262 fp CATCAATTTGTTATTGTTTTG 
ce phb-2 ORF  
pos. 169 rp CAATTAATTTGATCGTTATAC 
ce phb-2 ORF  
pos. 251 fp CACTTCAGAATCCCATGGTTC 
ce phb-2 ORF  
pos. 658 fp GAAAATTATGGGTTATGATC 
ce phb-2 ORF  
pos. 963 fp GAAGAACGATCCAGGATTTTTG 
emGFP fp GGCATGGACGAGCTGTACAA 
mPhb1 pos. 428 fp GAGAGCTGGTCTCCAG 
mPhb1 pos. 601 rp CCACCACAAATCTGGC 
mPhb2 pos. 416 fp GAGGTGCTCAAGAGTG 
mPhb2 pos. 548 rp CTGTGTACTCTCGGC 
pcDNA6 fp CGTGTACGGTGGGAGGTCTA 
pcDNA6 rp AGGAAAGGACAGTGGGAGTG 
pmec-17 pos. 216 rp TCTCTCCAACAAACTTATTGT 
 
Table 7. List of shRNAs 
shRNAs Sequence (5’  3’)/Clone ID 
mPhb2 shRNA 1 
bottom strand 
CCTGAGCTAAGTCCTAAGTTCTGGTCAGTCAGTGGCC
AAAACCAGAACTTGAAGGACTTAGCTC 
mPhb2 shRNA 1 top 
strand 
TGCTGAGCTAAGTCCTTCAAGTTCTGGTTTTGGCCACT
GACTGACCAGAACTTAGGACTTAGCT 
mPhb2 shRNA 2 CCTGTAACAATGGACCAGCACTCGTCAGTCAGTGGCC
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shRNAs Sequence (5’  3’)/Clone ID 
bottom strand AAAACGAGTGCTGCCGTCCATTGTTAC 
mPhb2 shRNA 2 top 
strand 
TGCTGTAACAATGGACGGCAGCACTCGTTTTGGCCAC
TGACTGACGAGTGCTGGTCCATTGTTA 
scrambled shRNA 
bottom strand 
CCTGAAATGTACTGCGTGGAGACGTCAGTCAGTGGCC
AAAACGTCTCCACGCGCAGTACATTTC 
scrambled shRNA top 
strand 
TGCTGAAATGTACTGCGCGTGGAGACGTTTTGGCCAC
TGACTGACGTCTCCACGCAGTACATTT 
 
Table 8. List of TaqMan® probes 
TaqMan® probe Assay ID Provider 
mHPRT  Mm01545399_m1 Applied Biosystems 
mPhb1  Mm01627033_g1 Applied Biosystems 
mPhb1  Mm00476104_m1 Applied Biosystems 
 
5.1.5 Plasmids 
Table 9. List of plasmids 
Plasmid Provider 
ce mec-2 L4440 J. Ahringer lab, Cambridge, England 
ce mev-1 L4440 J. Ahringer lab, Cambridge, England 
ce phb-1 L4440 generated for this thesis 
ce phb-2 L4440 J. Ahringer lab, Cambridge, England 
ce phb-2 pEntry generated for this thesis 
ce pmec-17 pEntry generated for this thesis 
ce pmec-17-phb-2::GFP-pDest generated for this thesis 
FLAG.hNEMO pcDNA6 Nephrolab Cologne 
FLAG.mPhb1 pcDNA6 generated for this thesis 
FLAG.mPhb2 pcDNA6 generated for this thesis 
FLAG.mPodocin pcDNA6 Nephrolab Cologne 
FLAG.RuvBl1 pcDNA6 Nephrolab Cologne 
L4440 A. Fire lab, Stanford, CA, USA 
mPhb2 pDonr 221 generated for this thesis 
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Plasmid Provider 
mPhb2 psiCheck Dest LR generated for this thesis 
mPhb2 shRNA1+2 pcDNA6.2 generated for this thesis 
mPhb2 shRNA1+2 pLenti4/TO/V5-
Dest generated for this thesis 
pLentiTTR Invitrogen 
pMD2 VSV-G Nephrolab Cologne 
pMDL g/p Nephrolab Cologne 
pRSV Nephrolab Cologne 
p∆R8.74 D. Trono lab, Lausanne, Switzerland 
scrambled shRNA pcDNA6.2 Nephrolab Cologne 
scrambled shRNA pLenti4/TO/V5-
Dest generated for this thesis 
scrambled shRNA TRIPZ Thermo Scientific 
V5.mPhb1 pcDNA6 generated for this thesis 
V5.mPhb2 pcDNA6 generated for this thesis 
 
5.1.6 Antibodies 
Table 10. List of primary antibodies 
Antigen (epitope) Clone Product 
no. 
Host dilution Provider 
cleaved caspase-3 (polyclonal) 9661 rabbit 1:200 IHC 
Cell 
Signaling 
Flag (DYKDDDDK) (polyclonal) F7425 rabbit 
1:10,000 
WB Sigma 
Flag (DYKDDDDK) 
M2 
(monoclonal) F3165 mouse 1 µg IP Sigma 
mec-2     rabbit 1:100 IF M. Chalfie 
PHB1 (C-terminal) 
Poly6031 
(polyclonal) 603101 rabbit 1:1000 WB BioLegend
PHB1/PHB2 mixed (monoclonal)   mouse undiluted IF 
newly 
generated 
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Antigen (epitope) Clone Product 
no. 
Host dilution Provider 
PHB2/BAP37  
(C-terminal) 
Poly6118 
(polyclonal) 611802 rabbit 
1:5 
Immunogold 
1:1000 WB BioLegend
podocin (amino-acid 
residues 367-383) (polyclonal) P0372 rabbit 1:100 IF Sigma 
V5 
(GKPIPNPLLGLDST) (polyclonal) AB3792 rabbit 1:2000 WB Millipore 
V5 
(GKPIPNPLLGLDST) 
SV5-Pk1 
(monoclonal) MCA1360 mouse 1 µg IP Serotec 
WT-1 (C-terminal) 
C-19 
(polyclonal) sc-192 rabbit 1:1000 IHC St. Cruz 
 
Table 11. List of secondary antibodies 
Antigen (epitope) Product no Dilution Provider 
Cy3-AffiniPure Donkey α-Rabbit IgG 
(H+L) 711-165-152 1:400 
Jackson 
ImmunoRe
search 
F(ab')2 fragment anti-rabbit IgG 
(H+L)-Biotin 711-066-152 1:500 Dianova 
gold-labeled goat anti-rabbit IgG  EM.GAR15 1:10 
BBInternati
onal 
Polyclonal goat anti-mouse 
immunoglobulins/HRP P0447 1:30,000 Dako 
Polyclonal goat anti-rabbit 
immunoglobulins/HRP P0448 1:30,000 Dako 
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5.1.7 Enzymes 
Table 12. List of enzymes 
Enzyme Product no. Provider 
Gateway® BP Clonase® II Enzyme 
Mix 11789020 Invitrogen 
Gateway® LR Clonase® II Enzyme 
Mix 11791100 Invitrogen 
MluI R0198 New England Biolabs 
Nco R0193 New England Biolabs 
NotI R0189 New England Biolabs 
SacI R0156 New England Biolabs 
T4 DNA Ligase EL0011 Fermentas 
 
5.1.8 Materials 
Table 13. List of materials 
Material Product no. Provider 
8-Lid chain, flat 65.989.002 Sarstedt 
10 cm dish for Agar Plates 82.1473 Sarstedt 
BD Microlance™ 3 27 G 3/4'' cannula 302200 BD Medical 
BD Plastipak™ syringe, 1 ml 300013 BD Medical 
BD Primaria™ cell culture dish 353803 BD Biosciences 
Blotting paper (Type BF4, 580 x 580) FT-2-521-
580580G 
VWR 
Cell culture dishes (12-well) 3513 Corning 
Cell culture dishes (6-well) 3516 Corning 
Cell culture dishes (10-cm) 430167 Corning 
Cell culture dish (96-well F-Form) 655180 Greiner BioOne 
Cell strainer, 100 µm 352360 BD Biosciences 
Combs (10 well, 1 mm) for acrylamide 
gels 
NC3010 Invitrogen 
Combs (15 well, 1 mm) for acrylamide 
gels 
NC3015 Invitrogen 
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Material Product no. Provider 
Cover glass (round 18 mm no. 1.5) 631-0153 VWR 
Cover glass (square18 mm no. 1.5) 631-0125 VWR 
Crymold® standard 4557 Sakura 
Discofix®-3 4098102 Braun 
Dounce glass-glass homogenizer   Wheaton 
Dynabeads® MPC®-S (magnetic 
particle concentrator) 
A13346 Invitrogen 
Fast Optical 96-well plates 4346907 Applied Biosystems 
Flask rectangular 25 cm2 431463 Corning 
Formvar/Carbon-coated nickel grids S162N Plano 
Gel cassette (1 mm) NC2010 Invitrogen 
Glass cuvette   WINZER 
Laborglastechnik 
Histosette® I M499-11 Simport 
Intrafix® SafeSet 4063000 Braun 
Polypropylene conical tube (15 ml) 188271 Greiner BioOne 
Polypropylene conical tube (50 ml) 227261 Greiner BioOne 
MicroAmp® Optical Adhesive Film 4311971 Applied Biosystem 
Micro tubes (1.5 ml) 72.690.001 Sarstedt 
Micro tubes (2 ml) 72.691 Sarstedt 
Millipore Immobilon-P Transfer 
Membranes  
T831.1 Carl Roth 
Multiple well cluster plate, 96-well 3596 Corning 
Multiply®-µStrip 0.2 ml chain 72.985.002 Sarstedt 
Nunc Cryotube™ 368632 Nunc 
Nunc-immuno frame 460348 Nunc 
Nunc-immuno module F8 maxisorb 
loose 
469949 Nunc 
Omnifix® Solo syringe, 10 ml 4617100V Braun 
PCR Soft-tubes 0.2 ml assorted 
colours 
711088 Biozym 
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Material Product no. Provider 
PCR Soft-tubes 0.2 ml clear 710920 Biozym 
PCR Soft-tubes 0.2 ml 8 Tubes/Flat 
Caps 
710970 Biozym 
Pipette tips (200 µl yellow) 70.760.002 Sarstedt 
Pipette tips (1000 µl blue) 70.762 Sarstedt 
Polypropylene column 34964 Qiagen 
Rotilabo®-syringe filters, 0.22 µm P666.1 Carl Roth 
Rotilabo®-syringe filters, 0.45 µm P667.1 Carl Roth 
Safe Lock 1.5 ml Eppendorf tubes 211-2130 VWR 
Stripettes (5 ml) 4051 Corning 
Stripettes (10 ml) 4101 Corning 
Stripettes (25 ml) 4251 Corning 
SuperFrost®/Plus microscope slides H867.1 Th.Geyer Group 
Syringe (PlastipakTM 1 ml) 7392/2007 BD 
TipOne (0.1-10 µl XL), sterile  S1110-3810-c Starlab 
TipOne (1-200 µl beveled), sterile S1111-1816-c Starlab 
TipOne (101-1000 µl graduated), 
sterile 
S1111-2831-c Starlab 
Venofix® Safety 21 G 3/4'' 4056520-01 Braun 
Weighing tray 140 x 140 mm 2159.1 Carl Roth 
Weighing tray 89 x 89 mm 2150.1 Carl Roth 
 
5.1.9 Equipment 
Table 14. List of equipment 
Equipment Model/Product no. Provider 
Analogue tube roller SRT6 Stuart 
Autoclave V-150 Systec 
Avanti centrifuge J-301 Beckman 
AxioCam ICc 1 Zeiss 
AxioCam MRm Zeiss 
Axiovert microscope 200M Carl Zeiss MicroImaging 
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Equipment Model/Product no. Provider 
Centrifuge (refrigerated) 5810 R Eppendorf 
Confocal microscope 
LSM/Axiobserver Z1 
LSM 710 Zeiss 
Cryostat CM1850 UV Leica 
Dumont #5 forceps 14098 WPI 
Dumont #55 forceps 14099 WPI 
Eppendorf Research® Multipipette 
(10-100 µl) 
3122000043 Eppendorf 
Fast Real-Time PCR System 7900HT ABI 
Fusion Solo chemiluminometer 60-FU-SOLO PeqLab 
Hamilton syringe (50 µl Type 705) 549-1155 VWR 
HERAcell Incubator  240 Heraeus 
HERAcell Incubator  150 Heraeus 
High-speed centrifuge (refrigerated) RC-5C plus Sorvall 
Horizontal electrophoresis system 1582 - 030305 Dan-Kar 
Incubator (Agarose) T 6030 Heraeus 
Innova Incubator Shaker 4400 New Brunswick Scientific
Inverted microscope CK2 Olympus 
JuLiTM Smart Fluorescence Cell 
Imager 
DBJ01B Bulldog Bio 
Laminar Flow Cabinet HS12 Heraeus 
MacsMix Tube Rotator MX100 Miltenyi Biotech 
Microcentrifuge   5424 Eppendorf 
Microcentrifuge (refrigerated) 5417R Eppendorf 
Microcentrifuge (refrigerated)  5415 R Eppendorf 
Microtome RM2235 Leica 
Mithras multimode microplate reader LB 940 Berthold Technologies 
Multifuge 4KR Heraues 
Nanodrop Spectrophotometer 1000 PeqLab 
Operating Scissor 501754 WPI 
Pipetboy acu 155 015 Integra Biosciences AG 
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Equipment Model/Product no. Provider 
Pipetman Pipette set (P2, P10, P100) F167500 Gilson 
Pipetman Pipette set (P20, P200, 
P1000) 
F167300 Gilson 
Power supply (for Dan-Kar system) EPS200 Pharmacia Biotech 
Powerpac 200 Power supply 1655052 Bio-Rad 
Powerpac 3000 Power supply 1655057 Bio-Rad 
Shaker  KS 260 IKA 
Suction Pump  MD 4C Vacuubrand 
TEM CCD camera Megaview III Olympus 
Thermal cycler (MJ mini) PTC-1148 Bio-Rad 
Thermomixer Comfort 1.5 ml 
Thermoblock 
5360 000.011 Eppendorf 
Thermomixer Comfort shaker & 
heating plate 
5355 000.011 Eppendorf 
Transmission electron microscope EM 902 Zeiss 
Transmission electron microscope JEM 1200 JEOL 
Ultra-centrifuge (Optima) TLX-120 Beckman 
Ultra-centrifuge rotor TLA-55 Beckman 
Ultracut UCT ultramicrotome EM FCS Leica 
Ultrasound homogenisator 
SONOPLUS 
HD2070 Bandelin 
Ultrasound water bath 2200 Branson 
UV Transilluminator system MW312 Intas 
Vannas Scissors 500086 WPI 
Vortex Mixer MS525-20 Heidolph (Reax) 
Water bath  WNB 22 Memmert 
Water bath (digital heating bath) HBR4 IKA 
Water bath (for paraffin sections) HI1210 Leica 
XCell SureLockTM Mini-Cell 
electrophoresis system 
100601-1408 Invitrogen 
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5.1.10 Software 
Table 15. List of software 
Software Version Provider 
Adobe Illustrator CS4 14.0.0 Adobe 
Adobe Photoshop  11.0.0.0 Adobe 
Axiovision 4.8 Carl Zeiss MicroImaging 
Edit-Seq 5.06 DNASTAR 
FinchTV 01.04.2000 Geospiza Inc. 
Fusion-CAPT 15.16 Vilber Lourmat 
Graphpad Prism 5 for Windows 5.2 GraphPad Software Inc. 
ImageJ/Fiji  1.46j Wayne Rasband 
Microsoft Office Suite 2003 Microsoft 
MikroWin  2000 Berthold Technologies 
Nanodrop 1000  3.7 Thermo Scientific 
SDS Software 2.4 Applied Biosystems 
ZEN Software 2009 Zeiss 
 
Table 16. List of online software 
Software (online) Website 
BLOCK-iT™ RNAi Designer http://rnaidesigner.invitrogen.com/rnaiexpress/ 
Ensembl.org http://www.ensembl.org/ 
NCBI Primerblast software http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
NCBI Pubmed  http://www.ncbi.nlm.nih.gov/pubmed/ 
NEB Double Digest Finder http://www.neb.com/nebecomm/doubledigestcalculator.
asp 
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5.2 Methods 
5.2.1 Working with nucleic acids 
5.2.1.1 Polymerase chain reaction (PCR) 
KOD Hot Start DNA Polymerase Kit was used for DNA amplification according to the 
manufacturer’s instructions. 100 ng template was used for amplification. Annealing 
temperature was chosen depending on the primer pair used (Primer Tm - (5-10) °C). 
5.2.1.2 Restriction and purification of plasmids, vectors and PCR products 
Plasmids and vectors for cloning were digested with the following protocol: 2 µg 
DNA, 1 µl restriction enzyme, 3 µl NEBuffer, 0,1 µg/µl BSA (depending on which 
enzyme was used) and filled up with H2O to 30 µl. After mixing, this solution was 
incubated for two hours at 37°C. Inserts were digested with the same protocol 
but - without considering the concentration - 15 µl of the purified PCR product 
(purification done with GeneJET™ Gel Extraction Kit according to manufacturer’s 
instructions) were applied to this mixture. After digestion the samples were loaded 
onto an agarose-gel and separated by applying an appropriate voltage. The expected 
bands were excised with a scalpel under UV light and purified by employing the 
GeneJET™ Gel Extraction Kit according to the manufacturer’s instructions. 
5.2.1.3 Ligation 
5 µl ligation buffer, 1 µl T4-Ligase and 1 - 2 µl digested, purified vector were mixed in 
a tube and filled up with H2O to 42 µl. The mixture was equally split into two tubes 
and 4 µl likewise digested and purified PCR product was added or 4 µl H2O as 
control. The samples were incubated for two hours at room temperature (RT) before 
transformation. 
5.2.1.4 Recombination 
For recombination 200 ng entry clone were mixed with 300 ng destination vector and 
filled up with TE buffer, pH 8.0, to 9 µl. The mixture was equally split into two tubes 
and 1 µl clonase or 1 µl H2O was added. After mixing by pipetting up and down, the 
reaction was incubated for one hour at 25°C. 0.5 µl Proteinase K solution was added 
to each sample, followed by an additional incubation for 10 minutes at 37°C to 
terminate the reaction. 
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5.2.1.5 RNA extraction and cDNA synthesis 
Cells were harvested in 500 µl Qiazol and RNA was extracted using the Direct-zol™ 
RNA MiniPrep Kit according to the manufacturer’s instructions. Quality of RNA was 
assessed by agarose gelelectrophoresis and measurement with a NanoDrop. cDNA 
was transcribed from 1 µg RNA with the High Capacity cDNA Reverse Transcription 
Kit according to the manufacturer’s instructions. 
5.2.1.6 TaqMan® assay 
For TaqMan® assays, the following mix was prepared: 12.5 µl TaqMan® Universal 
Mastermix II + 1.25 µl TaqMan® probe + 2 µl 25 ng/µl cDNA + 8 µl H2O. Cycling 
conditions: 95°C for 15 sec and 60°C for 1 min for 40 cycles. Analysis of the results 
was done by means of SDS software. 
5.2.1.7 DNA sequencing 
300 ng DNA were mixed with 2.25 µl sequencing buffer, 0.25 µl BigDye® Terminator 
and 2 pmol primer. The reaction was filled up with H2O to 10 µl. DNA was denatured 
for 1 min at 96°C. 40 cycles with the following conditions followed: 10 s, 96°C; 5 s, 
55°C; 4 min, 60°C. For the further procedure samples were given to the Cologne 
Center for Genomics (CCG), University of Cologne, Germany. Sequencings were 
analyzed by means of FinchTV. 
5.2.1.8 Dual-luciferase® reporter assay 
40.000 HEK293T cells were seeded into one well of a flat bottom 96-well plate in the 
evening. Next morning, cells were transfected using Lipofectamine® 2000. Therefore, 
mastermix 1 was prepared as follows: 80 µl Opti-MEM® was mixed with 
150 ng Phb2 psiCHECK™ Dest LR (modified from Promega’s psiCHECK™-2) and 
150 ng shRNA pcDNA™ 6.2-GW/emGFP-miR/eco31 (modified from Invitrogen’s 
pcDNA™ 6.2-GW/emGFP-miR). For mastermix 2, 80 µl Opti-MEM® was mixed with 
0.75 µl Lipofectamine® 2000 and incubated for five minutes. 80 µl of mastermix 1 was 
mixed with 80 µl mastermix 2 and incubated for 20 minutes. 50 µl of this mix was 
added to one well of the 96-well plate with HEK293T cells. Every transfection was 
done in triplicates. The Dual-luciferase® reporter assay was performed according to 
the manufacturer’s instructions by measuring firefly luciferase activity and Renilla 
luciferase activity with a Mithras LB 940 Microplate Reader. 
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5.2.2 Bacteria 
5.2.2.1 Chemical transformation of E.coli 
5 µl ligation product or 2 µl recombination product were mixed with 50 µl E.coli and 
incubated on ice for 30 minutes. After heat shock for 45 s at 42°C the bacteria were 
incubated on ice for additional two minutes. 350 µl SOC medium was added and the 
mixture placed on a 37°C-shaker for one hour (30°C for lentiviral constructs). 
Afterwards, 80 µl bacteria suspension was streaked out on LB plates including the 
respective antibiotics. The plates were dried for 15 minutes at RT and incubated 
overnight at 37°C (30°C for lentiviral constructs). Next day colonies were picked into 
LB medium including the respective antibiotics. Bacterial cultures were grown in a 
37°C-shaker (30°C for lentiviral constructs) overnight. 
5.2.2.2 Isolation of plasmid DNA and diagnostic digest 
DNA was isolated out of bacteria with GeneJet™ Plasmid Mini-Prep Kit or 
NucleoBond® Xtra Midi Kit according to the manufacturer’s instructions. 
Viral DNA constructs were filtered with a 0.22 µm syringe filter after elution. 
0.5 µg DNA was used for a diagnostic digestion with the appropriate enzymes. 
 
5.2.3 Cell culture 
5.2.3.1 Cells 
Conditionally immortalized mouse podocytes were generated as previously described 
[106,107] and cultured in RPMI-1640 media supplemented with 10% FBS, 
10 mM HEPES buffer, 1 mM sodium pyruvate and 5 ng/ml Interferone gamma. 
Differentiation was induced by culturing the cells at 37°C for 14 days on Primaria 
plastic plates (BD Biosciences) in the absence of Interferone gamma. All experiments 
were carried out with differentiated podocytes if not stated otherwise. HEK293T 
(human embryonic kidney cell line 293T) were maintained in DMEM media 
supplemented with 10% FBS. 
5.2.3.2 Freezing and thawing of cells 
For freezing, cells were washed with PBS once before the addition of 1 - 2 mL 
trypsin. After 1 - 5 minutes incubation at 37°C, medium containing 10% FBS was 
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added to stop the trypsin reaction. Cells were pelleted with a 5 minutes centrifugation 
at 200 x g, resuspended in cell freezing solution and transferred to a cryo tube for 
slow freezing. Storage of cells was done at -80°C or - for long-term storage - in liquid 
nitrogen. For thawing, a cryo tube with cells was quickly thawed up and the cell 
suspension transferred to a dish containing the appropriate medium. 
5.2.3.3 Passaging of cells 
Cells were washed once with PBS before the addition of 1 - 2 ml trypsin. After 
1 - 5 minutes incubation at 37°C, medium containing 10% FBS was added to stop the 
trypsin reaction. The desired amount of cell suspension was transferred to a new dish 
and filled up with the appropriate medium. 
5.2.3.4 Doxycycline-treatment of mouse podocytes 
Conditionally immortalized mouse podocytes expressing a Tetracycline repressor 
(pLenti6/TR) and a Tetracycline-inducible shRNA construct (shRNA construct in 
pLenti4/TO/V5-Dest) were differentiated as described under 5.2.3.1. After 10 days of 
differentiation, 2 µg/ml doxycycline was added to the medium and exchanged every 
24 hours. Experiments were performed after 96 hours of doxycycline-treatment. 
5.2.3.5 Transient expression of plasmids in 293T HEK cells 
HEK293T cells were transfected with a standard calcium-phosphate-method. 
Therefore, up to 20 µg plasmid- or vector-DNA were mixed with 500 µl CaCl2. 500 µl 
2x HEBS were added dropwise. The mixture was given to the cell media and after 
eight hours the medium was changed. Transfection efficiency (controlled by using a 
GFP plasmid) was controlled after 24 hours under the microscope. 
5.2.3.6 Virus production 
For pLenti6/TR or pLenti4/TO/V5-Dest virus production a mix of three helper 
plasmids was prepared as follows: 2.5 µg pRSV, 3.5 µg pMD2 VSV-G, 
6.5 µg pMDL g/p. 50 µl CaCl2 and 10 µg pLenti6/TR or pLenti4/TO/V5-Dest were 
mixed. After addition of 450 µl CaCl2 500 µl 2x HEBS were added dropwise. The 
mixture was given to the cell media of a 10 cm HEK293T dish. The reaction was 
stopped after eight hours by exchanging the medium. Virus production lasted 
72 hours. Then media were centrifuged for five minutes at 200 x g and the 
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supernatant was filtered through a 0.45 µm syringe filter. The virus supernatant was 
stored at 4°C until it was used for infection of cells. 
5.2.3.7 Infection of cells with virus and selection 
Mouse podocytes on one 10 cm cell dish were incubated with 5 ml medium, 
5 ml virus supernatant and 1x Polybrene. The medium was changed after 48 hours 
and infection efficiency was controlled under the microscope. Cells were treated for 
selection with the appropriate antibiotics until all cells on a non-infected control dish 
were dead. 
5.2.3.8 Immunofluorescence on cells 
For immunofluorescence staining of mouse podocytes, the cells were seeded on 
coverslips and differentiated at 37°C for 14 days. The cells were fixed in 4% 
paraformaldehyde for 15 minutes, washed three times with staining PBS before 
incubation in blocking solution and subsequently incubated with primary antibody 
overnight at 4°C in a humid chamber. After extensive washing with staining PBS an 
appropriate fluorophore-labeled secondary antibody was applied for one hour at RT 
in the dark. After three additional washing steps mounting was done in Prolong Gold 
antifade with DAPI. Images were acquired with an Axiovert 200 M microscope/EC 
Plan-Neofluar ×63/1.30 water immersion objective. Images were further processed 
using ImageJ/Fiji software version 1.46 and Adobe Photoshop CS4 version 11.0.0.0. 
 
5.2.4 Protein biochemistry  
5.2.4.1 Protein extraction 
HEK293T cells were detached from a 10 cm dish with PBS and centrifuged for 
5 minutes at 200 x g. The cell pellet was resuspended in 1 ml modified RIPA buffer 
including 44 µg/µl PMSF and 2 mM sodium orthovanadate as protease/phosphatase 
inhibitors. Mouse podocytes were scraped directly into 100 µl IP buffer including 
44 µg/µl PMSF and 2 mM Na3VO4 as protease/phosphatase inhibitors. The cell 
suspension was placed on ice for 15 minutes and vortexed every 3 - 5 minutes. A 
centrifugation at 4°C and 15.000 g for 15 minutes followed. The supernatant was 
transferred to a new vial and stored at -20°C. 
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5.2.4.2 Protein measurement 
To determine protein concentration the Pierce™ BCA protein assay kit was used. 5 µl 
of each sample or BSA standard (BSA standard prepared according to 
manufacturer’s instructions) were pipetted into one well of a flat-bottom 96-well plate. 
A mastermix of 150 µl BCA reagent A and 3 µl BCA reagent B was prepared and 
150 µl of this mastermix was added to each well of the flat-bottom 96-well plate 
containing either sample or BSA standard. The 96-well was incubated for 15 minutes 
at 37°C prior to measuring the absorption at 560 nm using a Mithras LB 940 
Microplate Reader. Every sample or BSA standard was measured in duplicates. 
5.2.4.3 Co-immunoprecipitation 
HEK293T cells were transiently transfected using the calcium phosphate-method 
described under 5.2.3.5. One day after transfection cells were harvested in 10 ml 
1x PBS and transferred to a 15 ml conical tube. Cells were pelleted by centrifugation 
at 200 x g for 1 minute at 4°C. The supernatant was discarded and the cell pellet 
resuspended in 1 ml modified RIPA buffer. The cell suspension was transferred to a 
new 1.5 ml vial and incubated on ice for 15 minutes prior to centrifugation at 
20,000 x g for 15 min at 4°C. 24 µl of the supernatant was preserved, mixed with 6 µl 
5× Laemmli, cooked for five minutes at 95°C and stored at -20°C for subsequent 
western blot analysis (i.e. lysate). The remaining supernatant was transferred to a 
new 1.5 ml vial and incubated with either 30 µl anti-FLAG(M2) antibody covalently 
coupled to agarose beads or with 1 µg of V5 antibody and 30 µl protein-G-sepharose 
beads, each for one hour at 4°C on an overhead shaker. After three washing steps 
(centrifugation at 1,000 x g for 1 minute at 4°C) with modified RIPA buffer, 30 µl of 
2x Laemmli was applied to the samples before incubation of the samples for 
5 minutes at 95°C. Samples were stored at -20°C. 
For endogenous co-immunoprecipitation, glomeruli were isolated as described under 
5.2.7.10. Isolated glomeruli were homogenized in 2 ml modified RIPA buffer with 
20 strokes in a dounce glass-glass homogenizer before sonication on ice (1.5 min, 
0.5 sec pulses). The suspension was transferred to a 2 ml tube and incubated on ice 
for 15 minutes prior to centrifugation at 20,000 x g for 15 min at 4°C. 24 µl of the 
supernatant was preserved, mixed with 6 µl 5× Laemmli, cooked for five minutes at 
95°C and stored at -20°C for subsequent western blot analysis (i.e. lysate). The 
remaining supernatant was split into two tubes and incubated with either 1 µg 
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podocin antibody (Sigma, host species: rabbit) and 30 µl of protein-A-sepharose 
beads or with 1 µg of Flag antibody (Sigma, host species: rabbit) and 30 µl of protein-
A-sepharose beads. After three washing steps (centrifugation at 1,000 x g for 1 
minute at 4°C) with modified RIPA buffer, 30 µl of 2x Laemmli was applied to the 
samples before incubation of the samples for 5 minutes at 95°C. Samples were 
stored at -20°C. 
5.2.4.4 SDS-polyacrylamide-gelelectrophoresis 
Each gel cassette was prepared by mixing 6 ml of resolving buffer with 
0.15% TEMED and 0.1% APS and adding a top layer of isopropanol. After 
hardening, isopropanol was removed and 1.7 ml stacking buffer mixed with 
0.15% TEMED and 0.1% APS was filled in. A 10-well or 15-well comb was inserted 
and the stacking gel was allowed to solidify. Gels were assembled into the XCell 
SureLock™ Mini-Cell electrophoresis system as per manufacturer’s instructions and 
the chamber was filled with running buffer so that the interior space between the gels 
was completely full and the exterior part was filled to a depth of 2 cm. Samples were 
loaded using a 50 µl Hamilton syringe which was cleaned four times with running 
buffer between each sample. 3 µl of Page-ruler Plus protein ladder were loaded on 
one well. Samples were diluted with Laemmli buffer to a final concentration of 
1x Laemmli and boiled for five minutes at 95°C before they were loaded onto the 
SDS-polyacrylamide-gel. Electrophoresis was done using a Powerpac 3000 with 
70 V for 30 minutes, followed by 1 hour 45 minutes at 25 mA per gel. 
5.2.4.5 Western Blot 
For Western Blot analysis the semi-dry method was used. Therefore, two squares of 
blotting paper as well as the polyacrylamide-gel were placed in transfer buffer. A 
Millipore Immobilon-P polyvinylidene difluoride (PVDF) membrane was soaked in 
methanol for one minute and then placed in transfer buffer as well. The blot was 
arranged as follows: one square of blotting paper, membrane, polyacrylamide-gel, 
one square of blotting paper. The protein transfer was achieved with a constant 
current of 12 V for 50 - 70 minutes. After transfer, the membrane was stained with 
Ponceau S to control for efficiency of the transfer. The membrane was incubated in 
5% BSA for one hour at RT, washed three times for five minutes with wash buffer 
followed by an overnight incubation with the primary antibody diluted in wash buffer 
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(antibody dilutions see section 5.1.6). On the next day the membrane was washed 
three times for five minutes with wash buffer and incubated for 30 minutes with the 
appropriate HRP-coupled secondary antibody diluted in wash buffer. Additonal 
three washing steps followed before either ECL detection solution or SuperSignal 
West Femto Chemiluminescent Substrate was applied to the membrane. Images 
were taken with FUSION-Solo™. 
5.2.4.6 Colloidal coomassie staining 
To test for albuminuria, 1 µl of urine was mixed with 4 µl of distilled water and 5 µl 
2x Laemmli. The mixture was incubated for five minutes at 95°C before separation on 
a SDS-polyacrylamid-gel (see section 5.2.4.4). The gel was incubated in 30 ml fixing 
solution for 30 minutes at RT on a shaker. Staining was done by applying 50 ml 
colloidal coomassie staining solution and incubation on a shaker at RT overnight. The 
gel was destained with distilled water before taking an image with a GS-800™ 
calibrated densitometer. 
 
5.2.5 Antibody production 
Antibody production was done in collaboration with Bernhard Schermer, Nephrolab 
Cologne, Germany. 
5.2.5.1 Purification of recombinant protein 
1 µl mPHB1 or mPHB2 pET30b Z Be (modified from Novagen’s pET30b(+)) was 
transformed into 10 µl chemo-competent BL21 bacteria as described under 5.2.2.1. 
100 µl of transformed bacteria were streaked out on an agar plate containing 
20 µg/ml kanamycin. Colonies were grown overnight at 37°C. Single colonies were 
picked into 3 ml 2x YTA containing 20 µg/ml kanamycin and incubated on a shaker at 
37°C for five hours. Two 1.5 ml tubes were filled with 1 ml bacteria culture each and 
IPTG was added to a final concentration of 1 mM into one of the two tubes. With a 
needle holes were poked into the lid of the tubes before shaking them for two hours 
at 37°C. Bacteria were pelleted by centrifugation at 16.000 x g for one minute at RT. 
Supernatant was discarded, the pellet resuspended in 100 µl 2x Laemmli and 
incubated for five minutes at 95°C. After separation of the samples in a SDS-
polyacrylamide-gel (see section 5.2.4.4) the gel was stained with colloidal coomassie 
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(see section 5.2.4.6) to identify well inducible clones. The remaining 1 ml bacteria 
culture of a well inducible clone was added to 100 ml 2x YTA containing 
20 µg/ml kanamycin and incubated overnight on a shaker at 37°C. 80 ml of this 
overnight culture were added to 1 l 2x YTA containing 20 µg/ml kanamycin and 
incubated on a shaker at 37°C until OD600 = 0.6 - 0.8 was obtained. IPTG was 
added in a final concentration of 1 mM and the culture incubated on a shaker at 30°C 
for additional five hours. Bacteria were pelleted with a centrifugation at 4000 x g for 
15 minutes at 4°C. Supernatant was discarded, the pellet resuspended in 35 ml His-
buffer and transferred to a 15 ml conical tube. 1 µg/ml DNase and 
200 µg/ml Lysozyme were added and the mixture was incubated on ice for 15 
minutes. 1 mM PMSF was added and the bacteria lysed by sonication (7 x 10% 
cycles for 30 seconds with 70% power; repeated 15 times). Lysis efficiency was 
checked by transferring 1 ml of lysate to a new 1.5 ml tube and centrifugation at 
20,000 x g for 10 minutes at 4°C. If the supernatant was yellow and cloudy the 
protocol was followed further, if it was white and clear another two repeats of 
sonication were applied and lysis efficiency was checked again. If lysis efficiency was 
ok, 1 ml of the supernatant (now called “crude lysate”) was transferred to a new 
1.5 ml tube and 30 µl Ni-NTA agarose was added. After incubation on an overhead 
shaker for 30 minutes at RT, the agarose was pelleted by centrifugation at 2,000 x g 
for two minutes at 4°C. The supernatant was transferred to a new 1.5 ml tube 
(= “flow-through”) while the agarose was washed three times with His-buffer. 
2x Laemmli was added to crude lysate, flow-through and pelleted Ni-NTA agarose in 
an appropriate amount to generate 1x Laemmli solutions. After incubation at 95°C for 
five minutes all samples and three different BSA standards (1 µg, 5 µg, 10 µg) were 
separated on a SDS-polyacrylamide-gel (see section 5.2.4.4) and stained with 
colloidal coomassie (see section 5.2.4.6). This gel was used to estimate the amount 
of protein in 1 ml of crude lysate. In parallel, the rest of the lysed bacteria were 
pelleted by centrifugation at 50,000 x g for 45 minutes at 4°C. The supernatant 
(=”crude lysate”) was filtered through a 0.45 µm filter into a new 50 ml conical tube. 
Depending on the previous estimation of protein concentration, 1 ml Ni-NTA agarose 
was added for each 10 mg protein in the crude lysate. This mixture was incubated on 
an overhead shaker overnight at 4°C. The next morning, a polypropylene column 
was moistened with 10 ml His-buffer. The mixture of crude lysate and Ni-NTA 
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agarose was applied to this column and the column washed with 50 ml His-buffer. 
Elution of His-tagged proteins from the Ni-NTA agarose was done by adding 
100 µl elution buffer and collecting the eluate in a new 1.5 ml tube. The elution step 
was done five times with fresh elution buffer. To estimate protein concentration 
5 µl of each eluate fraction was mixed with 5 µl 2x Laemmli, incubated for 
five minutes at 95°C and separated together with three BSA standards (1 µg, 5 µg, 
10 µg) on a SDS-polyacrylamide-gel (see section 5.2.4.4). The gel was stained with 
colloidal coomassie (see section 5.2.4.6). 
5.2.5.2 Immunization of mice and hybridoma generation 
80 µg of His-tagged PHB1 or His-tagged PHB2 were mixed with either 200 µl 
complete Freund’s adjuvant or 200 µl incomplete Freund’s adjuvant and 400 µl sterile 
water. The mixture was incubated in an ultrasound bath for three minutes and then 
vortexed for 20 minutes before uptake in a 1 ml syringe. A Balb/c mouse was i.m. 
injected every second day (four times in total) with 100 µl of this mixture containing 
either His-tagged PHB1 or His-tagged PHB2 (first injection with complete Freund’s 
adjuvant, next three injections with incomplete Freund’s adjuvant). Fusion with 
myeloma cells resulted in the generation of more than 40 prohibitin-1- and 
prohibitin-2-specific hybridoma cell lines producing monoclonal antibodies that were 
subcloned. 
5.2.5.3 ELISA 
Positive clones were identified by ELISA. Briefly, 200 ng His-tagged prohibitin-1, 
prohibitin-2 or a control protein were coupled to the wells of a Nunc immunosorb 
8-strip by incubation overnight at 4°C. After three washing steps with PBS-Tween the 
strips were blocked with 1% BSA in 1x PBS for one hour at RT. Three washing steps 
with PBS-Tween followed. 100 µl hybridoma supernatant was applied to the strips 
and incubated for one hour at RT. After three washing steps with PBS-Tween, the 
strips were incubated with a HRP-conjugated mouse antibody (dilution: 1:5000 in 
1x PBS) for one hour at RT in the dark. Three washing steps with PBS-Tween 
followed. 100 µl developer solution was applied to the strips and incubated for 
15 minutes at RT in the dark (blue color). The reaction was terminated by adding 
50 µl 2 N hydrochloric acid (yellow color). Absorption at 450 nm was measured with a 
Mithras LB 940 Microplate Reader. 
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5.2.6 Worm experiments 
All worm experiments were done in collaboration with Sibylle Brinkkötter and Puneet 
Bharill, Nephrolab Cologne, Germany. 
5.2.6.1 Worm strains 
TU3568 [sid-1(pk3321) him-5(e1490) V; lin-15B(n744) X; uIs71 [pCFJ90(myo-
2p::mCherry) + mec-18p::sid-1] were used, a kind gift of Prof. Martin Chalfie, 
Columbia University, New York [108]. Due to an integrated array containing mec-
18p::sid-1 in a sid-1 mutant background it provides efficient RNA interference only in 
touch receptor neurons. For microinjection of the mec-17p::phb-2::gfp transgene 
WTN2 animals were used [109]. All strains were cultured at 20°C. 
5.2.6.2 RNA interference 
RNA interference (RNAi) was performed by feeding as it is described previously 
[110,111] using the RNAi sensitized background of TU3568 worms. RNAi clones 
corresponding to the target genes phb-1, phb-2, mec-2 and mev-1 were used for 
knockdown experiments. Empty RNAi vector L4440 was used as control RNAi, 
mec-2 as positive control and mev-1, encoding another mitochondrial protein as 
control for unspecific RNAi effects based on an impairment of the mitochondrial 
respiratory chain. All clones except phb-1 were picked from an RNAi feeding library 
constructed by J. Ahringer’s laboratory at the The Wellcome CRC Institute, University 
of Cambridge, Cambridge, England [111]. To generate a phb-1 RNAi clone, a 0.8-kb 
fragment was PCR amplified using N2 genomic DNA as template and the primer pair 
ce phb-1 fp and rp as published previously [112]. A 0.656-kb NcoI/SacI fragment was 
cloned into the likewise digested L4440 vector. The construct was electroporated into 
HT115 bacteria. Bacteria containing the different knockdown plasmids were seeded 
onto nematode growth medium - isopropyl-thio-β-d-galactoside (NGM–IPTG) plates. 
Plates were kept 16 hours at RT for generation of dsRNA.  
Worm eggs were harvested by bleaching gravid adult animals in 0.5 N NaOH and 
2 - 4% NaOCl. The eggs were washed in M9 buffer, placed on the seeded plates and 
grown at 20°C. Young adult hermaphrodites were tested for touch sensation as 
described under 5.2.6.3. 
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5.2.6.3 Touch assay 
Animals were tested for response to gentle touch as described previously [113]. 
Briefly, each animal was touched 10 times by a thin hair at the anterior part of the 
body. Stopping or backward movements were scored and shown as touch response 
out of ten touches. The data was generated in three independent experiments using 
>= 15 worms each time for each data point. Statistical evaluation was done as 
described under 5.2.7.11. 
5.2.6.4 Microinjection 
For germline injection, the phb-2::gfp plasmid was prepared via multisite gateway 
cloning. Briefly, the promoter of mec-17 (mec-17p) was cloned from a C. elegans 
library and recombined into pDONR P4-P1R according to the manufacturer’s 
protocol. phb-2 was cloned without stop codon from the same library and recombined 
into pDONR 221 according to the manufacturer’s protocol. Both, mec-17p and phb-2 
were recombined from the pEntr plasmids into pDest MB14 to generate a plasmid 
expressing PHB-2::GFP under control of the mec-17 promoter. 
Lines containing extrachromosomal arrays were generated by injecting the phb-2::gfp 
plasmid at a concentration of 50 ng/ul mixed with pmyo-2::mCherry as a co-injection 
marker at the concentration of 5 ng/ul into WTN2. Single positive transgenic 
F1 worms were moved onto NGM plates and allowed to proliferate to form different 
lines.  
Microinjection was performed in the lab of A. Antebi, MPI for Biology of Ageing, 
Cologne, Germany. 
5.2.6.5 Immunofluorescence on worms 
Antibody stainings on mec-17p::phb-2::gfp transgenic worms were performed using a 
modified Finney-Ruvkun protocol [114,115]. 1.25 ml fixing solution was added to a 
tube with worms and kept on dry ice for 2 - 3 hours. The worms were thawed again 
on ice, centrifuged at 400 x g for two minutes and the supernatant was discarded. 
The worms were washed with Tris-Triton-Buffer (TTB) once. After resuspension in 
1% β-mercaptoethanol/TTB the worms were incubated at 37°C for two hours, 
centrifuged at 400 x g for two minutes and the supernatant was discarded. Worms 
were first resuspended in 1x borate buffer, the buffer was discarded and replaced by 
10 mM DTT in 1x borate buffer. After gentle shaking for 15 minutes the buffer was 
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discarded and the worms washed with 1x borate buffer once. Worms were shaken for 
15 minutes in 0.3% H2O2/1x borate buffer and washed again with 1x borate buffer. 
Next, the worms were incubated in antibody buffer B for 15 minutes. The specimen 
finally was incubated with a rabbit antibody detecting the N-terminus of MEC-2 (kind 
gift of Prof. Martin Chalfie; dilution 1:200 in antibody buffer A) for two hours at RT. 
Several washing steps with antibody buffer B were followed by incubation with a 
Cy3-labeled secondary antibody diluted in antibody buffer A for two hours at RT (for 
dilution see section 5.1.6). After extensive washing with antibody buffer B the worms 
were mounted on slides with ProLong Gold antifade reagent with DAPI. Images were 
captured with an LSM 710/Axiobserver Z1 confocal microscope x40/1.1 water 
immersion objective operated by ZEN 2009 software. Images were further processed 
using ImageJ/Fiji software version 1.46 and Adobe Photoshop CS4 version 11.0.0.0. 
 
5.2.7 Mouse experiments 
5.2.7.1 Mouse strains and animal care 
Mice in which exons 3 and 4 of the Phb2 gene are flanked by two loxP sequences 
[53] were mated to either NPHS2.Cre mice [116] or Tamoxifen-inducible 
podocin-iCreER(T2) [117] to generate podocyte-specific Phb2 knockout mice 
Phb2 flox/flox;NPHS2.Cre (Phb2pko) or tamoxifen-inducible podocyte-specific Phb2 
knockout mice Phb2 flox/flox;podocin-iCreER(T2) (podocin-iCreER(T2) Phb2pko). The 
animals were backcrossed onto the C57/Bl6 background for at least 10 generations. 
Mice from both genders carrying the conventional NPHS2.cre transgene were 
included while only male mice of the Phb2 flox/flox;podocin-iCre(ER(T2) were used. 
Mice were housed according to the standardized specific pathogen-free conditions in 
the University of Cologne animal facility. The Animal Care Committee of the 
University of Cologne reviewed and approved the experimental protocol. The mice 
were sacrificed once they lost 15 - 20% of their maximal body weight following 
federal animal care regulations. Renal tissue was embedded in OCT compound and 
frozen at -80°C or fixed in 4% neutral buffered formalin for 24 hours before paraffin-
embedding. 
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5.2.7.2 Serum analysis 
Blood samples were collected in the fifth week of life with a 1 ml syringe and a 
27 G cannula (both washed with heparin) from anesthetized mice. Blood samples 
were centrifuged at 3000 x g for 10 minutes at 4°C, supernatant (= serum) 
transferred to a new tube and given to the Institute for Clinical Chemistry of the 
University Hospital of Cologne, Germany, for quantification of serum urea and 
creatinine. 
5.2.7.3 Extraction of DNA from mouse tissue 
To obtain DNA from mouse tissue (ear tag or tail cut) for genotyping purposes, the 
tissue was mixed with 100 µl base solution. After incubation for 30 minutes at 95°C, 
100 µl neutralization solution was added and the mixture stored at 4°C. 
5.2.7.4 Polymerase-chain reaction (PCR) for genotyping purposes 
For genotyping-PCRs Promega’s GoTaq® Flexi DNA Polymerase was used 
according to the manufacturer’s instructions. For sequences of primers see section 
5.1.4, Table 5. For Phb2 genotyping PCR the following mix was prepared: 5.5 µl H2O 
+ 12.5 µl 1x RedTaq Mix + 1 µl 10 µM Phb2 fp + 0.5 µl 10 µM Phb2 rp1 + 
0.5 µl 10 µM Phb2 rp2 + 5 µl template. Cycling conditions for Phb2 genotyping PCR: 
1.) 2 minutes at 95°C; 2.) 30 sec at 95°C; 3.) 30 sec at 62°C; 4.) 45 sec at 72°C; 
5.) repeat step 2.) - 4.) 39 times; 6.) 1 min 30 sec at 72°C. Size of expected 
fragments: wildtype = 378 bp, floxed allele = 506 bp. 
For Insr genotyping PCR the following mix was prepared: 13.6 µl H2O + 
5 µl 5x Green Flexi buffer + 1.5 µl 25 mM MgCl2 + 0.2 µl 10 mM dNTPs + 
1 µl 10 µM Insr fp + 1 µl 10 µM Insr rp + 0.2 µl 5 U/µl GoTaq® + 2.5 µl template. 
Cycling conditions for Insr genotyping PCR: 1.) 2 minutes at 95°C; 2.) 30 sec at 
95°C; 3.) 45 sec at 58°C; 4.) 45 sec at 72°C; 5.) repeat step 2.) - 4.) 29 times; 
6.) 1 min 30 sec at 72°C. Size of expected fragments: wildtype = 200 bp, floxed 
allele = 250 bp. 
For Igf1r genotyping PCR the following mix was prepared: 13.6 µl H2O + 
5 µl 5x Green Flexi buffer + 1.5 µl 25 mM MgCl2 + 0.2 µl 10 mM dNTPs + 1 µl 10 µM 
Igf1r fp + 1 µl 10 µM Igf1r rp + 0.2 µl 5 U/µl GoTaq® + 2.5 µl template. Cycling 
conditions for Igf1r genotyping PCR: 1.) 2 minutes at 95°C; 2.) 30 sec at 95°C; 
3.) 30 sec at 54°C; 4.) 40 sec at 72°C; 5.) repeat step 2.) - 4.) 24 times; 
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6.) 1 min 30 sec at 72°C. Size of expected fragments: wildtype = 300 bp, floxed 
allele = 350 bp. 
For Podocin-Cre genotyping PCR the following mix was prepared: 10.6 µl H2O + 
5 µl 5x Green Flexi buffer + 1.5 µl 25 mM MgCl2 + 0.2 µl 10 mM dNTPs + 
1.25 µl 10 µM β-globin fp + 1.25 µl 10 µM β-globin rp + 1.25 µl 10 µM Cre fp + 
1.25 µl 10 µM Cre rp +0.2 µl 5 U/µl GoTaq® + 2.5 µl template. Cycling conditions for 
Podocin:Cre genotyping PCR: 1.) 2 minutes at 95°C; 2.) 45 sec at 95°C; 3.) 60 sec at 
59°C; 4.) 45 sec at 72°C; 5.) repeat step 2.) - 4.) 29 times; 6.) 1 min 30 sec at 72°C. 
Size of expected fragments: internal control (β-globin band)  = 494 bp, Cre 
allele = 269 bp. 
For Podocin-iCreER(T2) genotyping PCR the following mix was prepared: 
11.6 µl H2O + 5 µl 5x Green Flexi buffer + 1.5 µl 25 mM MgCl2 + 0.2 µl 10 mM dNTPs 
+ 1 µl 10 µM Dicer fp + 1 µl 10 µM Dicer rp + 1 µl 10 µM iCreER(T2) fp + 
1 µl 10 µM iCreER(T2) rp + 0.2 µl 5 U/µl GoTaq® + 2.5 µl template. Cycling 
conditions for Podocin-iCreER(T2) genotyping PCR: 1.) 2 minutes at 95°C; 2.) 45 sec 
at 95°C; 3.) 30 sec at 57°C; 4.) 45 sec at 72°C; 5.) repeat step 2.) - 4.) 34 times; 
6.) 1 min 30 sec at 72°C. Size of expected fragments: internal control (β-globin band) 
 = 351 bp, iCreER(T2) allele = 500 bp. 
5.2.7.5 Albumin ELISA 
Albumin concentration in mouse urine was measured by using a mouse albumin 
ELISA kit according to the manufacturer’s instructions. 
5.2.7.6 Creatinine Assay 
Creatinine concentration in mouse urine was measured by using a creatinine 
(urinary) assay kit according to the manufacturer’s instructions. 
5.2.7.7 PAS staining 
Paraffin sections were deparaffinized in Histo-Clear (Xylene-like) and rehydrated in 
graded ethanol. After five minutes incubation in distilled water the sections were 
incubated in 0.9% periodic acid for 10 minutes. After washing for one minute in 
distilled water the sections were incubated for 10 minutes in Schiff’s reagent. An 
additional washing step for two minutes in tap water followed before the sections 
were incubated in Mayer’s hematoxylin solution for 10 minutes. After eight minutes in 
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tap water the sections were dehydrated in graded ethanol and Histo-Clear. Mounting 
was done with Histomount. 
5.2.7.8 Specific immunohistochemistry 
Indirect immunoperoxidase staining was performed on formalin-fixed tissue. 4 μm 
thin tissue sections were deparaffinized in Histo-Clear and rehydrated in graded 
ethanol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase 
in methanol for 15 minutes. After five minutes incubation in tap water the sections 
were either treated with Proteinase K solution 15 minutes (for 
podocin-immunohistochemistry (IHC)), cooked for 10 minutes in 10 mM citrate buffer, 
pH 6 (for cleaved caspase-3- IHC) or cooked for 10 minutes in Tris-EDTA-Tween (for 
phosphorylated S6 ribosomal protein- and WT-1-IHC) followed by three washing 
steps for three minutes in TBS. Blocking was done for 20 minutes in 1% BSA in TBS 
followed by three washing steps for three minutes in TBS. Solution A was applied for 
15 minutes and then the sections were incubated with solution B for 15 minutes. After 
three washing steps for three minutes in TBS the sections were incubated overnight 
at 4°C with primary antibody diluted in TBS (for dilutions see section 5.1.6). The 
sections were washed repeatedly in TBS before incubation for one hour at RT with 
biotinylated mouse anti-rabbit secondary antibody diluted in 1% BSA in TBS. The 
ABC kit was used according to the manufacturer’s instructions for signal amplification 
and 3,3′-diaminobenzamidine (DAB) was used as a chromogen. Sections were 
counterstained with hematoxylin for 10 seconds and washed for three minutes under 
running tap water. After dehydration in graded ethanol and Histo-Clear the sections 
were covered with Histomount. In the procedure of specific immunohistochemistry for 
phosphorylated S6 ribosomal protein washing was always done with TBS-Tween and 
blocking with 1% BSA in TBS was skipped. 
Images were acquired with an Axiovert 200 M microscope/EC Plan-Neofluar x40/1.3 
oil immersion or ×63/1.20 water immersion objective equipped with a charge-
coupled-device camera. Images were further processed using ImageJ/Fiji 
softwareersion 1.46j. 
Specific immunohistochemistry for cleaved caspase-3 was done in collaboration with 
Andreas Linkermann, Christian-Albrechts University, Kiel, Germany. 
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5.2.7.9 Electron microscopy and immunogold labeling 
Mice were perfused with electron microscopy fixation buffer and the kidneys post-
fixed in the same buffer for two weeks at 4°C. Sample osmication with 1% osmium 
tetroxid in 0.1 M cacodylate and dehydration in a graduated ethanol series as well as 
infiltration and flat embedding using the epoxy embedding medium kit was done 
according to the manufacturer’s instructions. Thin (30 nm) cross sections were taken 
on an Ultracut UCT ultramicrotome. The sections were stained with 1.5% aqueous 
uranylic acetate and examined with a Zeiss EM 902 electron microscope. For 
immunogold labeling, fixed samples of mouse or human kidneys were embedded in 
acrylic Lowicryl® K4M resin according to the manufacturer’s instructions and 
polymerized in gelatin capsules at -35°C under UV light for 24 hours followed by 
incubation at RT under UV light for 48 hours. Ultrathin sections (80 nm) were 
collected on Carbon coated nickel grids and quenched in 1% BSA/0.1 M Tris for 
10 minutes. For mouse sections the antibody was diluted 1:5 in EM antibody buffer, 
for human sections 1:10 in electron microscopy antibody buffer. Sections were 
incubated with the antibody dilution for two hours at RT, washed three times for 
five minutes in 0.1 M Tris before incubation with 15 nm of gold-labeled goat 
anti-rabbit IgG (diluted 1:10 in electron microscopy antibody buffer) for one hour at 
RT. The sections were washed once in 0.1 M Tris and thrice in ddH2O. After staining 
with 2% aqueous uranyl acetate for 14 minutes and Reynold’s lead citrate for 
10 minutes the sections were examined with a JEOL JEM 1200 transmission electron 
microscope. Images were further processed with Adobe Photoshop CS4 version 
11.0.0.0. 
Electron microscopy was done in collaboration with Prof. Bloch, German Sport 
University Cologne, Germany. Immunogold labeling was done in collaboration with 
Prof. Kerjaschki, Medical University of Vienna, Austria. 
5.2.7.10 Glomeruli isolation 
For glomeruli isolation, the mouse was sacrificed and both kidneys together with the 
aorta were taken out and placed in a 10 cm dish with 1x HBSS. The aorta was cut 
open from the dorsal side to get access to the renal arteries. 100 µl tosylactivated 
Dynabeads M-450 were mixed with 10 ml 1x HBSS and 1 ml of this mixture was 
injected into each kidney with a 1 ml syringe and 27 G cannula via the renal artery. 
Kidneys were decapsulated and transferred to a 2 cm dish. They were cut into pieces 
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with a scalpel and digested with 2 ml of 1 mg/ml Collagenase in 1x HBSS for 
20 minutes on a shaker at 37°C. At first, this mixture was actively pressed through a 
100 µm cell strainer into a 50 ml conical tube and the cell strainer was washed with 
10 ml 1x HBSS. Then the solution was passively filtered through a new 100 µm cell 
strainer into a fresh 50 ml conical tube and the cell strainer was again washed with 
10 ml 1x HBSS. After centrifugation at 300 x g for five minutes at 4°C the supernatant 
was discarded and the pellet resuspended in 2 ml 1x HBSS. The glomeruli were 
isolated by consecutive washing steps with a magnetic bead separator. Purity and 
quality of glomeruli was checked under the microscope. 
5.2.7.11 Tamoxifen diet 
Eight weeks old animals were exposed to a tamoxifen-enriched diet (400mg/kg, 
Harlan Laboratories) ad libitum for six weeks. Based on a daily intake of 5 g of food 
per mouse, this corresponded to an oral dose of 2 mg/d tamoxifen per mouse. To 
exclude any potential side effects in females only male mice were used. 
5.2.7.12 Rapamycin injection 
For rapamycin injections the protocol published by Zeng et al.[118] was used with 
some modifications. Animals received daily i.p. injections of either rapamycin solution 
or vehicle solution starting two weeks after birth until they were sacrificed because of 
weight loss or sickness. Phb2pko were injected with either 3 µg rapamycin solution 
per g body weight (i.e. 10 µl 0.3 mg/ml rapamycin solution per g body weight) or the 
same amount of vehicle solution (i.e. 10 µl vehicle solution per g body weight). 
Phb2fl/fl mice received 3 µg rapamycin solution per g body weight (i.e. 10 µl 0.3 mg/ml 
rapamycin solution per g body weight). The rapamycin solution was always freshly 
prepared directly before injection from the rapamycin stock solution, which was 
stored at -20°C. 
 
5.2.8 Human tissue 
5.2.8.1 Immunofluorescence on human tissue 
Human tissue samples were obtained from tumor nephrectomy samples after 
obtaining written consent as approved by the local ethic committee. The tissue was 
fixed in 4% paraformaldehyde for 15 minutes, washed three times with staining PBS 
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before incubation in blocking solution and subsequently incubated with primary 
antibody overnight at 4°C in a humid chamber. After extensive washing with staining 
PBS an appropriate fluorophore-labeled secondary antibody was applied for 
one hour at RT in the dark. In the meantime, 1 µg podocin-antibody was labeled with 
the Zenon® Tricolor rabbit IgG labeling kit according to the manufacturer’s 
instructions. After three additional washing steps, the tissue was incubated with the 
Zenon-labeled podocin antibody for 60 minutes in the dark. Three additional washing 
steps and a post-fixation with 4% paraformaldehyde for 15 minutes followed. After 
three more washing steps, mounting was done in Prolong Gold antifade with DAPI. 
Images were acquired with an LSM 710/Axioobserver Z1 confocal microscope 
x40/1.1 water immersion objective operated by ZEN 2009 software. Images were 
further processed using ImageJ/Fiji software version 1.46 and Adobe Photoshop CS4 
version 11.0.0.0. 
 
5.2.9 Statistical analysis 
All results are expressed as means ± SEM. Statistical significance was evaluated 
using GraphPad Prism version 4.00c for Macintosh and OASIS (Online Application 
for the Survival Analysis of Lifespan Assays) [119]. Unpaired Student’s t-test was 
applied in most experiments except for survival analysis experiments where a Log 
Rank test [120] was performed. A P-value <0.05 was considered significant. 
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6 Results 
6.1 Loss of PHB2 leads to severe glomerular disease 
6.1.1 Podocyte-specific Phb2-knockout mice (Phb2pko) develop albuminuria 
and die prematurely 
To generate a mouse line for investigation of the function of PHB2 in podocytes 
conditional Phb2 flox/flox mice [53] were mated to podocyte-specific Cre mice 
(NPHS2.cre mice) [116]. The murine Phb2 gene is located on chromosome 6 and is 
composed of nine exons. In the Phb2 flox/flox mouse loxP sites are inserted 
upstream of exon 3 and downstream of exon 4 of the Phb2 gene. Expression of a 
Cre-recombinase leads to deletion of the loxP-flanked exons and causes a frameshift 
mutation resulting in a stop of translation at amino acid 73. The truncated PHB2 
protein product is inactive [53]. 
All mice were born following Mendelian rules (Figure 4A) and no overt differences 
became evident at birth. Interestingly, podocyte-specific Phb2-deficient mice 
(Phb2pko) did not survive longer than 31 - 37 days while all Cre-negative mice 
(Phb2fl/fl) developed normally and did not show any signs of glomerular disease 
(Figure 4B). Analysis of the urinary albumin-to-creatinine ratio, which was used to 
determine the amount of albuminuria, revealed progressive albuminuria in Phb2pko 
mice but not Phb2fl/fl mice over time. 14 days after birth albuminuria was detectable in 
neither Phb2pko mice nor control mice whereas after 21 days Phb2pko mice showed 
already pronounced albuminuria. At day 28 a maximum albumin-to-creatinine ratio of 
430 mg/mg was reached in Phb2pko mice (Figure 4C). In line with this finding, 
Phb2pko mice gained less weight compared to control mice already evident at day 22 
resulting in a wasting syndrome after day 29 (Figure 4D). Serum creatinine and 
serum urea levels were measured to assess renal function. Serum creatinine (Figure 
4E) as well as serum urea levels (Figure 4F) were significantly increased in 
Phb2pko mice but not control mice in their fifth week of life. This is further supporting 
the observation that podocyte-specific loss of PHB2 results in podocyte dysfunction, 
renal failure and eventually causes premature death. 
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Figure 4. Podocyte-specific Phb2-knockout mice (Phb2pko) develop albuminuria and 
die prematurely 
(A) Phb2 flox/flox;NPHS2.cre mice are born following Mendelian rules (Phb2fl/wt, 
Phb2 flox/wt;NPHS2.cre wt/wt; Phb2fl/fl, Phb2 flox/flox;NPHS2.cre wt/wt; Phb2het, 
Phb2 flox/wt;NPHS2.cre tg/wt; Phb2pko, Phb2 flox/flox;NPHS2.cre tg/wt). (B) Kaplan-
Meier survival curve showed decreased survival of Phb2pko mice compared to control 
mice (n = 5 for Phb2fl/fl / het, n = 6 for Phb2pko) (C) Measurement of urinary albumin-to-
creatinine ratio revealed progressive albuminuria in Phb2pko mice (albumin-to-
creatinine ratio day 14: Phb2fl/fl 0.09 ± 0.03 mg/mg, n = 4, vs. 
Phb2pko 0.37 ± 0.21 mg/mg, n = 4; P > 0.05; albumin-to-creatinine ratio day 21: 
Phb2fl/fl 0.65 ± 0.16 mg/mg, n = 4, vs. Phb2pko 193.10 ± 26.81 mg/mg, n = 4; 
***P < 0.001; albumin-to-creatinine ratio day 28: Phb2fl/fl 0.57 ± 0.07 mg/mg, n = 4, 
vs. Phb2pko 470.40 ± 131.30 mg/mg, n = 4; **P < 0.01). (D) Analysis of body weight 
from postnatal day 14 until day 32 (Phb2fl/fl or Phb2het vs. Phb2pko at days 28/29, 
*P<0.05 and at days 30-32 with **P < 0.01, n = 3 for Phb2fl/fl and n = 4 for Phb2het 
and Phb2pko). (E) Measurement of serum creatinine levels of mice in their fifth week 
of life showed increased serum creatinine in Phb2pko mice (Phb2fl/fl / het 14.74 ± 
3.75 µmol/l vs. Phb2pko 74.73 ± 2.20 µmol/l, n = 3 for both groups; ***P < 0.001). (F) 
Measurement of serum urea levels of mice in their fifth week of life showed higher 
serum urea levels in Phb2pko mice than control mice (Phb2fl/fl / het 44.00 ± 7.02 mg/dl 
vs. Phb2pko 493.70 ± 45.34 mg/dl, n = 3 for both groups; ***P < 0.001). 
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6.1.2 Phb2pko mice develop glomerulosclerosis 
To gain a better insight into the development of glomerular disease in Phb2pko mice 
the animals were analyzed at different time points. Glomerulogenesis in mice is 
completed 14 days after birth. Therefore, the phenotypic analysis of Phb2pko mice 
was started at this time point and ended with 28 days after birth, which is close to the 
death of the animals. 
To assess glomerular morphology PAS staining of kidney sections from Phb2pko mice 
at day 14, 21 and 28 were analyzed. Despite albuminuria being present already at 
day 21 no changes in glomerular morphology became evident before day 28. Here, 
the mice presented with tubular protein casts as well as glomerular scarring i.e. 
glomerulosclerosis (Figure 5A). Podocin was used as a marker for the integrity of the 
slit diaphragm. Podocin stainings revealed a regular garland-like pattern of podocin 
at day 14 in Phb2pko mice. One week later, at day 21, podocin stainings appeared 
weaker and more granular indicative of an injured slit diaphragm. 28 days after birth 
podocin expression was nearly completely lost (Figure 5B). Electron micrographs 
revealed already at day 14 first subtle changes in foot process organization. In some 
areas foot process structures were completely normal while other areas showed 
beginning broadening of the processes. This became even more evident at day 21 
when the regular foot process structure is lost nearly everywhere within a glomerulus 
and adjacent processes flattened. At day 28 Phb2pko mice completely lost the 
glomerular structure (Figure 5C). Since PHB2 is known as a mitochondrial protein 
and previous reports already showed defects in mitochondrial morphology upon loss 
of PHB2 [53,69] the cristae structure of podocytic mitochondria in Phb2pko mice was 
analyzed in electron micrographs. 14 days after birth no changes in mitochondrial 
morphology were seen. However, at day 21 the lamellar cristae structure of 
mitochondria in Phb2pko mice was lost and the podocytes contained swollen 
mitochondria with disorganized cristae structures (Figure 5D). Because of the severe 
phenotype and complete loss of the glomerular structure an analysis of mitochondrial 
morphology in 28 days old Phb2pko mice was not possible. 
Taken together, Phb2pko mice did not only show defects in mitochondrial morphology 
but also lost foot process organization and developed glomerulosclerosis. 
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Figure 5. Phb2pko mice develop glomerulosclerosis 
Genotypes and time points as indicated in the figure. (A) PAS staining of kidney 
sections revealed protein casts in the tubular system and glomerulosclerosis at 
day 28 in Phb2pko mice (scale bar 20 µm). (B) Immunohistochemistry for podocin on 
kidney sections showed reduction of podocin expression over time in Phb2pko mice 
(scale bar 20 µm). (C) Analysis of podocyte foot processes in electron micrographs 
revealed progressive foot process effacement in Phb2pko mice (scale bar 0.7 µm). (D) 
Analysis of mitochondrial morphology in electron micrographs showed swollen and 
disorganized mitochondria in 21 days old but not 14 days old Phb2pko mice (arrows; 
scale bar 0.3 µm). FP, podocyte foot processes; GBM, glomerular basement 
membrane; EC, endothelial cells. 
 
6.1.3 Phb2het mice present with changes in mitochondrial ultrastructure 
To further understand the defect in Phb2pko mice an electron micrograph analysis of 
Phb2het mice was performed. These mice do not show any loss of body weight or 
albuminuria but electron micrographs of 21 days old Phb2het mice revealed partially 
disorganized mitochondrial cristae structures, whereas foot process organization was 
normal (Figure 6A+B). 
Thus, changes in mitochondrial ultrastructure do not necessarily lead to glomerular 
disease. 
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Figure 6. Phb2het mice present with changes in mitochondrial ultrastructure 
(A) Electron micrograph analysis of mitochondrial cristae structures of Phb2het mice 
at day 21 revealed partially disorganized mitochondrial cristae structures (arrow = 
normal mitochondrial structure; arrowheads = defective mitochondrial structure; scale 
bar 1 µm). (B) Electron micrograph analysis of foot process organization of 
Phb2het mice at day 21 showed no overt changes in foot process organization (scale 
bar 1 µm). 
 
6.1.4 Glomeruli of Phb2pko mice display no increased rate of apoptosis at 
day 21 
Previous reports showed that loss of prohibitin-2 might render cells more susceptible 
to apoptosis [53,69,121,122]. Loss of the terminally differentiated podocyte cannot be 
compensated and seems to cause the development of albuminuria and 
glomerulosclerosis in other models of glomerular diseases [123–126].  
To investigate if loss of podocytes causes the severe phenotype in this mouse model, 
kidney sections of the albuminuric Phb2pko mice at day 21 and non-albuminuric 
control mice of the same age were stained for cleaved caspase-3, a marker for 
apoptotic cell death. However, no increased cleavage of caspase-3 was detected in 
podocytes of Phb2pko mice (Figure 7A). Since podocyte loss does not necessarily 
depend on apoptosis but could also be attributed to other types of cell death the total 
number of podocytes per glomerulus was assessed. Therefore, kidney sections of 
three animals per genotype were stained for the podocyte marker protein WT-1. 
Podocytes from 40 glomeruli of each kidney section were counted. Interestingly, no 
change in podocyte cell number was detected at day 21 in Phb2pko mice compared to 
Phb2fl/fl mice (Figure 7B+C). 
Therefore, podocyte loss did not account for the development of albuminuria in 
Phb2pko mice. 
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Figure 7. Glomeruli of Phb2pko mice display no increased rate of apoptosis at day 21 
(A) Immunohistochemistry for cleaved caspase-3 on kidney sections of Phb2pko and 
Phb2fl/fl mice revealed no cleaved caspase-3-positive cells in the glomeruli of both 
genotypes (scale bar 20 µm). (B) Immunohistochemistry for the podocyte marker 
WT-1 on kidney sections of Phb2pko and Phb2fl/fl mice (scale bar 20 µm). (C) 
Quantification of WT-1-positive cells per glomerulus showed no difference in 
Phb2pko mice compared to Phb2fl/fl mice (Phb2fl/fl 11.96 ± 0.65 WT-1-positive 
cells/glomerulus vs. Phb2pko 11.32 ± 0.57 WT-1-positive cells/glomerulus; n = 3 for 
both groups, 40 glomeruli per animal counted, P > 0.05). 
 
6.1.5 PHB2 is required to maintain structural integrity of podocyte foot 
processes 
In the past decades, several studies on proteins of the slit diaphragm complex 
showed that an intact slit diaphragm structure is essential for a healthy glomerulus 
and normal albumin filtration [13,16,18,19,127]. Therefore, the structure of the slit 
diaphragm was analyzed in Phb2pko mice more closely by means of electron 
microscopy.  
In 14 days old Phb2pko mice no overt changes in slit diaphragm appearance were 
detected (Figure 8A). However, at day 21 Phb2pko mice developed foot process 
effacement and loss of slit diaphragm structures became evident (Figure 8B). 
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Thus, although slit diaphragm structures between neighboring podocytes were 
initially formed Phb2pko mice failed to maintain them over time. 
 
 
Figure 8. PHB2 is required to maintain structural integrity of podocyte foot processes 
(A) Electron micrographs revealed no overt changes in slit diaphragm appearance in 
14 days old Phb2pko mice (arrows point to slit diaphragm structures in Phb2pko mice; 
scale bar 0.3 µm). (B) Electron micrographs demonstrated foot process effacement 
and loss of slit diaphragm structures in 21 days old Phb2pko mice (arrow heads, scale 
bar 0.3 µm). 
 
6.1.6 Inducible depletion of Phb2 results in loss of slit diaphragm function 
First differences in foot process organization were already seen 14 days after birth. 
To exclude a developmental phenotype in Phb2pko mice a second mouse model was 
used. Mating of tamoxifen-inducible improved Cre mice under the control of the 
NPHS2 promoter (podocin-iCreER(T2)) [117] to conditional Phb2 flox/flox mice [53] 
resulted in podocin-iCreER(T2) Phb2pko animals (tPod-Phb2pko) and podocin-
iCreER(T2) Phb2het animals (tPod-Phb2het). These mice were fed with a tamoxifen-
enriched diet starting at the age of eight weeks for six weeks in total to induce Cre 
expression in adult animals. Only male mice were used for this study to exclude 
potential side-effects of tamoxifen in female mice.  
PAS-staining at 2.5 weeks after end of tamoxifen treatment revealed 
glomerulosclerosis and tubular protein casts in tPod-Phb2pko but not tPod-Phb2het 
mice (Figure 9A). Furthermore, at this time point podocin expression was highly 
reduced in these animals (Figure 9B). Analysis of urinary samples of tPod-Phb2pko 
mice in a coomassie gel detected albuminuria already in the last week of tamoxifen 
feeding (Figure 9C). However, the time of onset of albuminuria and time of death 
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varied inbetween two weeks in all mice that were analyzed, probably due to different 
amounts of intake of the tamoxifen-enriched diet. 
Taken together, the phenotype of the Phb2pko mice was not developmental and could 
be reproduced in adult animals. 
 
 
Figure 9. Inducible depletion of Phb2 results in loss of slit diaphragm function 
(A) PAS staining revealed glomeruloscerosis in tPod-Phb2pko but not 
tPod-Phb2het mice 2.5 weeks after the end of tamoxifen treatment (scale bar 20 µm). 
(B) Immunohistochemistry for podocin on kidney sections of tPod-Phb2pko and control 
mice showed loss of podocin expression 2.5 weeks after the end of tamoxifen 
treatment (scale bar 20 µm). (C) Coomassie stain of urinary samples detected 
albuminuria in tPod-Phb2pko but not control mice at day 37 of tamoxifen treatment. 
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6.2 PHB2 as a novel slit diaphragm protein 
6.2.1 PHB2 localizes to the slit diaphragm 
As loss of PHB2 not only resulted in premature death after 4-5 weeks but also led to 
massive albuminuria already evident three weeks after birth we tested the hypothesis 
that PHB2 exerts extramitochondrial functions in podocytes. To this end we assessed 
the localization of PHB2. Therefore, a new antibody was generated because the 
commercially available antibodies directed against PHB1 and PHB2 gave no 
reproducible results on tissue sections. Human kidney sections were stained with this 
self-generated antibody detecting both, PHB1 and PHB2. Co-staining for podocin 
showed a partial co-localization of PHB1/2 and podocin at the sit diaphragm (Figure 
10A). The PHB1/2 antibody was validated using a co-staining with MitoTracker on 
immortalized podocytes (Figure 10B) and an ELISA (Figure 10C). To further prove 
the localization of PHB2 to the slit diaphragm immunogold labelings were performed. 
Immunogold labeling of a commercially available PHB2 antibody showed a clear 
signal in podocytes close to the slit diaphragm (Figure 10D) and – used as a proof of 
principle control – in mitochondria (Figure 10E). In addition, immungold labeling with 
a PHB1 antibody was performed but did not give any specific signals in mitochondria 
or other parts of the cell. 
Thus, PHB2 localized not only to mitochondria but also to the slit diaphragm of 
podocytes. 
 
Results 
66 
 
 
Figure 10. PHB2 localizes to the slit diaphragm 
(A) Immunofluorescence stainings of podocin and PHB1/2 on human kidney sections 
showed partial co-localization (arrows show the overlap; scale bar 50 µm in overview, 
10 µm in magnification). (B) ELISA for PHB1, PHB2 and a control protein measured 
in triplicates. (C) Co-staining of MitoTracker and PHB1/2 on mouse podocytes (scale 
bar 20 µm).  (D) Immunogold labeling of PHB2 in mouse and human kidney sections 
detected PHB2 at the slit diaphragm (arrows). (E) Immunogold labeling of PHB2 
revealed signals in mitochondria (arrow). 
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6.2.2 PHB1 and PHB2 co-immunoprecipitate with podocin 
Previous worked already showed that podocin is an important player at the slit 
diaphragm [33,36]. Since both, podocin and PHB2, localized to the slit diaphragm we 
next tested the hypothesis that both proteins co-immunoprecipitate. To test this, 
co-precipitation experiments after overexpression in HEK293T cells were performed. 
For these experiments, the known interaction of PHB1 and PHB2 served as a 
positive control. PHB2 co-immunoprecipitated with podocin and vice versa (Figure 
11A+B). In addition, the interaction of PHB1 and podocin was tested and 
co-immunoprecipitation showed a co-immunoprecipitation of PHB1 with podocin and 
vice versa (Figure 11C+D). Both proteins did not co-immunoprecipitate with a control 
protein. To further substantiate this finding co-immunoprecipitations were performed 
with endogenous proteins. To this end, glomeruli from wildtype mice were isolated 
and proteins extracted before the respective antibodies were added. Here, PHB2 
co-immunoprecipitated with podocin as well (Figure 11E). Due to technical reasons 
no conclusive result for the co-precipitation of PHB1 with podocin from glomerular 
lysates can be shown. 
Taken together, PHB2 not only localized to the slit diaphragm but also 
co-immunoprecipitated with podocin in overexpression and glomerular lysates. 
Co-immunoprecipitation of PHB1 with podocin could only be shown in 
overexpression experiments. 
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Figure 11. PHB1 and PHB2 co-immunoprecipitate with podocin 
(A) HEK293T cells were transiently transfected as stated. Immunoprecipitation was 
performed using a V5 antibody and showed co-precipitation of PHB2 with podocin 
but not the control protein. (B) HEK293T cells were transiently transfected with the 
indicated constructs. Immunoprecipitation was performed using a FLAG antibody and 
showed co-precipitation of podocin with PHB2 but not the control protein. (C) 
HEK293T cells were transiently transfected with the constructs as stated. 
Immunoprecipitation was performed using a FLAG antibody and showed 
co-precipitation of PHB1 with podocin but not the control protein. (D) HEK293T cells 
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were transiently transfected with the indicated constructs. Immunoprecipitation was 
performed using a V5 antibody and showed co-precipitation of podocin with PHB1 
but not the control protein. (E) Co-immunoprecipitation of podocin and PHB2 from 
isolated mouse glomeruli revealed co-precipitation of PHB2 with podocin 
endogenously. 
 
6.2.3 PHB-2 co-localizes with MEC-2 at touch receptor punctae and 
regulates touch sensation in C. elegans 
Localization of PHB2 to the slit diaphragm and its interaction with podocin point to an 
additional, extramitochondrial role of PHB2 in podocytes. This could of course also 
imply a functional relevance of PHB2 at the slit diaphragm complex. However, in 
mammals, no assays are currently available to test the functionality of the slit 
diaphragm experimentally. To circumvent this problem the nematode C. elegans can 
be utilized [24]. In C. elegans, six touch receptor neurons are necessary for 
conducting gentle body touch [113,128]. In these touch receptor neurons MEC-2 
- the C. elegans homolog of podocin - is part of the multiprotein-channel complex that 
is localized in regular punctae along touch receptor neuron processes [42,43]. 
A new transgenic worm strain was generated that expressed PHB-2::GFP under 
control of the mec-17 promoter, which is exclusively active in the six-touch receptor 
neurons [129]. In this transgenic strain PHB-2 was found around the cell body of the 
neurons most likely reflecting the mitochondrial localization of the protein. 
Additionally, staining of these worms for MEC-2 revealed a partial co-localization of 
PHB-2 and MEC-2 along the touch punctae (Figure 12A), thereby confirming the 
results on localization of PHB2 from section 6.2.1. 
The mechanosensory machinery in C. elegans and the complex organization of the 
slit diaphragm in mammals show a high similarity [24,130]. In C. elegans the 
multiprotein-channel complex is needed to convert mechanical forces into electrical 
signals, thus representing a physiological response to study by performing gentle 
touch assays. To achieve optimal knockdown of genes in neurons of C. elegans a 
neuronal-specific RNAi strain [sid-1(pk3321) him-5(e1490) V; lin 15B(n744) X; uIs71 
[pCFJ90(myo-2p::mCherry) + mec-18p::sid-1]] can be used. By using this strain, the 
cell metabolism in any other cell of the body is not affected. As a whole body 
knockout of phb-2 leads to infertility and shortened lifespan [70] the restriction of the 
knockdown to the neurons was important to exclude an influence of metabolic 
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changes in other cells on gentle body touch. Feeding of the neuronal-specific RNAi 
strain with bacteria carrying a mec-2-RNAi plasmid impaired touch sensitivity as 
reported previously [113]. Loss of either phb-1 or phb-2 significantly decreased touch 
sensitivity but to a lesser extent compared to mec-2 deficiency. To exclude a 
potential effect of defects of the respiratory chain on touch sensitivity the worms were 
also fed with mev-1 RNAi. Mev-1 encodes for the succinate dehydrogenase 
cytochrome b, i.e. the respiratory chain complex II and its knockdown causes 
disruption of mitochondrial respiration [131]. However, loss of mev-1 resulted only in 
a slight decrease in touch sensitivity while the difference between mev-1-deficient 
and phb-1- or phb-2-deficient worms was still highly significant (Figure 12B). 
In summary, PHB-2 co-localized with MEC-2 at touch receptor punctae in C. elegans. 
Both, PHB-1 and PHB-2 were needed to conduct touch sensation, which was most 
likely independent of respiratory chain activity. 
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Figure 12. PHB-2 co-localizes with MEC-2 at touch receptor punctae and regulates 
touch sensation in C. elegans 
(A) Immunofluorescence stainings of MEC-2 on PHB-2::GFP expressing worms 
showed co-localization of PHB-2 and MEC-2 in touch punctae (arrows point at co-
localization in a touch receptor neuron). (B) Touch sensitivity was reduced upon loss 
of either mec-2, phb-1 or phb-2 but not mev-1. (control RNAi 9.42 ± 0.09 
responses/10 touches, mev-1 RNAi 9.02 ± 0.10 responses/10 touches, phb-1 RNAi  
6.58 ± 0.21 responses/10 touches, phb-2 RNAi 6.80 ± 0.21 responses/10 touches, 
mec-2 RNAi 3.38 ± 0.22 responses/10 touches; n = 50 for all groups; ***P < 0.001 for 
control RNAi vs. phb-1 RNAi, control RNAi vs. phb-2 RNAi, mev-1 RNAi vs. phb-1 
RNAi and mev-1 RNAi vs. phb-2 RNAi). 
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6.3 PHB2 in metabolic signaling 
6.3.1 Podocyte-specific knockout of the insulin receptor (Insr) and IGF-1 
receptor (Igf1r) prolongs survival of Phb2pko mice 
In worms and yeast the deleterious effects of a phb-2/Phb2-deficiency could be 
reversed by either loss of the insulin receptor homolog daf-2 or dietary restriction 
[70,71]. However, nothing is known about the impact of PHB2 on insulin signaling 
and the mTOR pathway in mammalian cells. 
To investigate if Phb2pko mice benefit from loss of insulin signaling and show reduced 
albuminuria and/or prolonged survival two new mouse models were generated. First, 
Phb2 flox/flox mice were mated to Igf1r flox/flox or Insr flox/flox mice. Second, these 
mice were mated to podocyte-specific Cre mice (NPHS2.cre mice) [116] to obtain 
mice with a podocyte-specific deficiency of either Phb2 and Igf1r 
(Phb2pko/Igf1rpko mice) or Phb2 and Insr (Phb2pko/Insrpko mice). 
Survival analysis revealed that an additional Igf1r-deficiency did not influence the 
survival rate of Phb2pko mice (Figure 13A+C). In contrast, Phb2pko/Insrpko as well as 
Phb2pko/Insrhet mice outlived Phb2pko mice by 6 days in average (Figure 13B+C). The 
survival benefit reached statistically significant levels for Phb2pko/Insrpko mice (Figure 
13C) and all mice developed progressive albuminuria, short-lived Phb2pko/Igf1rpko as 
well as longer-lived Phb2pko/Insrpko mice (Figure 13D). 
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Figure 13: Loss of the insulin receptor but not IGF-1 receptor prolongs lifespan of 
Phb2pko mice 
(A) Kaplan-Meier survival curve revealed that the survival time of Phb2pko mice is not 
changed by an additional Igf1r-deficiency (n = 6 for Phb2pko/Igf1rpko, n = 4 for 
Phb2pko/Igf1rhet, n = 6 for Phb2pko). (B) Kaplan-Meier survival curve showed that an 
additional knockout of the insulin receptor (Insr) prolonged lifespan of Phb2pko mice 
(n = 3 for Phb2pko/Insrpko, n = 3 for Phb2pko/Insrhet, n = 6 for Phb2pko). (C) Statistical 
analysis comparing all genotypes with Phb2pko mice. (D) Representative coomassie 
stain of urinary samples revealed albuminuria in podocyte-specific double 
knockout-mice irrespective of their genotype. 
 
Since the insulin receptor may compensate for the IGF-1 receptor and vice versa 
[132] a podocyte-specific triple knockout mouse line of Phb2, Insr and Igf1r was 
generated (Phb2pko/Insrpko/Igf1rpko). 
Analysis of survival rates showed that Phb2pko/Insrpko/Igf1rpko, Phb2pko/Insrhet/Igf1rpko 
and Phb2pko/Insrpko/Igf1rhet mice lived longer than Phb2pko mice (Figure 14A) but this 
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increased survival was only statistically significant for Phb2pko/Insrpko/Igf1rpko and 
Phb2pko/Insrpko/Igf1rhet mice (Figure 14B). In accordance to the results in 
Phb2pko/Igf1rpko and Phb2pko/Insrpko mice all analyzed genotypes of the triple knockout 
mice presented with massive albuminuria and there were no differences observed 
between the different genotypes (Figure 14C).  
 
 
Figure 14: Podocyte-specific knockout of the insulin receptor (Insr) and IGF-1 receptor 
(Igf1r) prolongs survival of Phb2pko mice 
(A) Kaplan-Meier survival curve revealed prolonged survival of 
Phb2pko/Insrpko/Igf1rpko, Phb2pko/Insrhet/Igf1rpko and Phb2pko/Insrpko/Igf1rhet mice (n = 19 
for Phb2pko/Insrpko/Igf1rpko, n = 9 for Phb2pko/Insrhet/Igf1rpko, n = 11 for 
Phb2pko/Insrpko/Igf1rhet, n = 9 for Phb2pko/Insrhet/Igf1rhet, n = 6 for Phb2pko). (B) 
Statistical analysis comparing all genotypes with Phb2pko mice. (C) Representative 
coomassie stain of urinary samples showed albuminuria in all analyzed mice 
irrespective of their genotype (x = no urine analyzed because mouse was dead by 
that time). 
 
6.3.2 Inhibition of mTOR signaling increases lifespan of Phb2pko mice 
To study the role of PHB2 in metabolic signaling of podocytes in more detail a new 
Phb2-knockdown podocyte cell culture model was established. In 2008, Merkwirth et 
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al. showed that Phb2-deficiency leads to a reduced proliferation rate of the affected 
cells [53]. Therefore, the use of a doxycycline-inducible knockdown cell culture model 
was necessary. To generate an inducible Phb2 knockdown in mouse podocytes, 
short hairpin RNAs (shRNAs) directed against the murine Phb2 mRNA were 
designed, cloned and tested for knockdown-efficiency with a dual-luciferase assay in 
mPhb2-transfected HEK 293T cells. The combination of shRNA1 and shRNA4 gave 
the best knockdown result as calculated by the renilla/firefly ratios and was used for 
further studies (Figure 15A). The selected shRNAs were transferred into a 
doxycycline-inducible lentiviral vector (pLenti4-TO, Invitrogen) and thermo-sensitive 
immortalized mouse podocytes [107] were stably transduced with this vector (cell line 
named mPhb2 shRNA). To control for off-target effects another cell line was 
generated which inducibly expressed a scrambled shRNA. The Phb2 knockdown was 
confirmed by using a TaqMan® assay with probes specific for Phb1 and Phb2, 
showing a decrease in mRNA expression of Phb2 but not Phb1 (Figure 15B). 
Western Blot analysis of these cells revealed significantly reduced protein levels of 
PHB1 and PHB2 (Figure 15C). This is in accordance with previous results showing 
that PHB1 and PHB2 interdepend and each protein needs the other for its stability 
[50,53,112]. In addition, the cells presented with a disrupted mitochondrial network as 
visualized by immunofluorescence staining for the mitochondrial marker protein 
Tom20 that resides within the outer mitochondrial membrane (Figure 15D+E).  
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Figure 15. Generation and validation of an inducible Phb2 shRNA podocyte cell line 
(A) Knockdown efficiency of different shRNAs targeting murine Phb2 mRNA was 
assessed by dual-luciferase assay in 293T cells (n = 3; bars represent 
means ± SEM). (B) mPhb2 shRNA podocytes contained less Phb2 mRNA than 
control (scrambled shRNA) podocytes as assessed in a TaqMan® assay (n = 3, bars 
represent mean ± SEM, ***P < 0.001). (C) Western Blot analysis revealed decreased 
protein levels of PHB1 and PHB2 in mPhb2 shRNA podocytes. Staining for 14-3-3 
was used as a loading control. (D) mPhb2 shRNA podocytes presented with a 
disrupted mitochondrial network as seen by immunofluorescence staining with a 
Tom20 antibody (scale bar 10 µm). (E) Quantification of tubular and fragmented 
mitochondrial morphology revealed more fragmented mitochondria in mPhb2 shRNA 
podocytes (n = 100 cells for mPhb2 shRNA, n = 108 cells for scrambled shRNA).  
 
Western Blot analysis of these Phb2-deficient mouse podocytes revealed an 
overactive signaling via the mTOR pathway as seen by increased phosphorylation of 
the downstream effector S6 ribosomal protein (Figure 16A+B). This could be 
blocked by treating the cells with the mTORC1-specific inhibitor rapamycin (Figure 
16A). To show the importance of PHB2 for this signaling pathway not only in cell 
culture, but also in tissue, kidney sections of Phb2pko and Phb2fl/fl mice were stained 
for phosphorylated S6 ribosomal protein in immunohistochemistry. Interestingly, 
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Phb2pko but not control mice showed increased activation of S6 ribosomal protein 
within glomeruli (Figure 16C). 
To investigate if the increased mTOR activity plays a role in the development of 
glomerular disease in Phb2pko mice the mice were treated with the mTORC1-specific 
inhibitor rapamycin starting at the age of two weeks. At this age glomerulogenesis 
was completed and Phb2pko mice did not present with albuminuria yet as described in 
section 6.1.2. Rapamycin treatment had no effect on control Phb2fl/fl mice. In 
contrast, treatment of Phb2pko mice with rapamycin prolonged the mean lifespan by 
10 days compared to vehicle-treated Phb2pko mice (Figure 16D+E). Analysis of 
urinary samples in coomassie gels showed massive albuminuria in both, 
vehicle-treated and rapamycin-treated Phb2pko mice (Figure 16F). 
Thus, loss of PHB2 influenced signaling of the mTOR pathway, but treatment with 
rapamycin could prolong lifespan of short-lived Phb2pko mice despite progressive 
albuminuria. 
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Figure 16. Inhibition of mTOR signaling increases lifespan of Phb2pko mice 
(A) Phb2-deficient mouse podocytes showed higher levels of phosphorylated S6 
ribosomal protein than control podocytes, which could be blocked by treatment with 
10 ng/ml rapamycin (pS6RP = phosphorylated S6 ribosomal protein, S6RP = S6 
ribosomal protein). (B) mPhb2 shRNA podocytes had a higher ratio of pS6RP/S6RP 
than control (scrambled shRNA) podocytes as assessed by densitometric 
quantification (n = 5, bars represent mean ± SEM, **P < 0.01) (C) 
Immunohistochemistry for phosphorylated S6 ribosomal protein (pS6RP) on kidney 
sections revealed increased levels of pS6RP in glomeruli of Phb2pko compared to 
Phb2fl/fl mice (arrows point to cells showing a signal for pS6RP; scale bar 20 µm). (D) 
Kaplan-Meier survival curve revealed that treatment of Phb2pko mice with rapamycin 
prolonged survival for several days compared to vehicle-treated Phb2pko mice (n = 7 
for Phb2fl/fl + rapamycin, n = 7 for Phb2pko + vehicle, n = 8 for Phb2pko + rapamycin). 
(E) Statistical analysis comparing rapamycin-treated Phb2pko mice with vehicle-
treated Phb2pko mice. (F) Representative coomassie stain of urinary samples showed 
development of albuminuria in vehicle- as well as rapamycin-treated Phb2pko mice 
(x = no urine analysed because mouse was dead by that time).
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7 Discussion 
7.1 PHB2 – a slit diaphragm protein? 
7.1.1 The phenotype of Phb2pko mice is similar to slit diaphragm 
protein-deficient mice 
More than 5% of all human beings worldwide suffer from chronic kidney diseases 
(CKD) with great impact on quality of life and rising socio-economical burdens on our 
societies. Glomerular disorders, with diabetic nephropathy being the leading cause, 
account for the majority of cases of CKD. In the past several years, accumulating 
evidence suggested that glomerular podocytes are crucial for the function of the 
kidney filter and critically involved in the development of proteinuria [5,6]. Mutations in 
several genes encoding for proteins of the slit diaphragm are a major cause for the 
development of focal segmental glomerulsclerosis (FSGS). One of the most studied 
proteins at the slit diaphragm is podocin, a member of the SPFH domain protein 
family. Mutations in podocin cause childhood onset of proteinuria and 
steroid-resistant forms of focal segmental glomerulosclerosis (FSGS) [16,17,37–41]. 
So far, nothing is known about the function of other SPFH domain-containing 
proteins in podocytes, which could also be important for the development of 
proteinuria and glomerular disease. 
PHB2 - another member of the SPFH domain-containing protein family - is known as 
an integral mitochondrial membrane protein. In addition to its functions in 
mitochondrial biogenesis and maintenance of mitochondrial DNA PHB2 seems to be 
involved in lots of other cellular processes like cellular signaling and apoptosis 
[54,133,134].  
To study the function of PHB2 in podocyte biology a podocyte-specific 
Phb2-knockout mouse (Phb2pko) was generated. The mice were born viable in the 
expected Mendelian frequency. Starting at about three weeks of age the animals 
showed growth retardation as compared to their littermate controls. Phb2pko animals 
died at the age of 31 to 37 days. To obtain a better insight in podocyte biology the 
glomerular phenotype at different time points was analyzed. 14 days after birth, when 
glomerular development is completed, light microscopy of renal sections did not 
reveal any injury. Glomerular function as examined by urine albumin/creatinine ratios 
was normal. EM analysis revealed normal mitochondrial architecture. One week later 
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podocin expression was reduced and changed to a more granular pattern, indicating 
a change in slit diaphragm organization. In accordance to this, EM analysis of 
Phb2pko mice demonstrated highly effaced foot processes, loss of slit diaphragm 
structures and the animals developed albuminuria. Mitochondria structure was 
disorganized and with multiple swollen cristae structures. At four weeks of age, PAS 
staining revealed severe glomerulosclerosis and high levels of serum urea and serum 
creatinine revealed the progression of the disease to renal failure, leading to 
premature death. Podocin expression was markedly reduced and foot processes 
were completely effaced, which was also reflected in high, nephrotic-range levels of 
albuminuria. In summary, podocytes of Phb2pko mice showed not only disorganized 
mitochondrial cristae structures but also defects in foot process organization and slit 
diaphragm maintenance. 
Interestingly, apart from loss of proper mitochondrial ultrastructures, these findings 
resemble the phenotype of mice lacking important components at the slit diaphragm. 
For example, CD2AP is part of the podocyte slit diaphragm complex and interacts 
with the slit diaphragm protein nephrin [135]. CD2AP-knockout mice exhibit growth 
retardation starting three weeks after birth and die three to four weeks later. The 
animals develop proteinuria at day 14 and present with glomerulosclerosis at about 
four weeks of age [10]. Nephrin- or podocin-knockout mice show massive foot 
process effacement and rapidly develop proteinuria as well. While nephrin-knockout 
mice die within one day after birth, podocin-knockout animals survive some days or 
even weeks [18,136]. To explain the differences in the onset of proteinuria and time 
of death between nephrin-, podocin- and CD2AP-knockout mice it was speculated 
that other proteins might compensate for the function of podocin and CD2AP. This 
could explain the slower time course of the disease in these animals compared to 
nephrin-knockout mice [136]. A second explanation would be the variance in genetic 
backgrounds, which has been shown to influence the severity of glomerular diseases 
[18,137]. 
However, the highly comparable phenotype of Phb2pko mice and other slit diaphragm 
protein-knockout mice is not the only argument for a slit diaphragm-related 
phenotype of Phb2pko animals: despite first signs of structural changes at the slit 
diaphragm at day 14 mitochondria of Phb2pko mice were unaffected and 21 days old 
Phb2het mice did not show an overt glomerular phenotype albeit disturbed 
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mitochondrial ultrastructure. Taken together, these findings point to an 
extramitochondrial function of PHB2 as an important factor for the maintenance of the 
kidney filtration barrier. 
 
7.1.2 PHB2 is necessary for the function of the slit diaphragm complex 
Podocin and prohibitins are required for proper structural organization of their 
immediate surrounding at the slit diaphragm or mitochondria, respectively. Together 
with the initial findings in the Phb2pko mice this raised the hypothesis that PHB2 may 
not only localize to mitochondria but also to the slit diaphragm and interact with 
podocin to further stabilize the protein-lipid supercomplex at the slit diaphragm. 
Therefore, localization of PHB2 in podocytes was assessed. PHB2 was found - in 
addition to its known mitochondrial localization - close to the slit diaphragm in 
immunogold labelings as well as immunofluorescences stainings. Overexpression as 
well as endogenous experiments revealed co-immunoprecipitation of PHB2 with the 
slit diaphragm protein podocin. With regard to previous reports showing PHB2 
interacting and being stabile only in a complex with PHB1 it is very likely that PHB1 
may also localize to the slit diaphragm. Overexpression experiments suggest a 
co-immunoprecipitation of podocin and PHB1. However, due to technical limitations, 
co-immunoprecipitation studies for PHB1 using glomerular lysates as well as 
immunogold labelings remained inconclusive.  
The localization of PHB2 to the slit diaphragm protein-lipid supercomplex was further 
confirmed in C. elegans. Here, the PHB2 homolog (PHB-2) co-localized with the 
podocin homolog MEC-2 in mechanosensitive complexes along touch receptor 
punctae of the neurons. As a transgenic strain was utilized in which expression of the 
transgene was under the control of the mec-17 promoter mislocalization due to 
overexpression as compared to the endogenous phb-2 promoter and/or due to the 
GFP-tag cannot be excluded. However, a similar approach has been used previously 
to analyze localization of prohibitins in worms [70]. To assess the functionality of the 
complex a neuronal-specific RNAi strain was fed with either phb-1 or phb-2 RNAi and 
gentle touch assays were performed. Interestingly, phb-1- and phb-2-deficient worms 
showed a reduced response to gentle touches as compared to the control RNAi fed 
worms, suggesting a functional impact of PHB1 and PHB2 on the complex. Loss of 
mev-1, a component of the mitochondrial electron transport chain complex II, showed 
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only mild effects on mechanosensation. This indicates that the effect of phb-1- and 
phb-2-deficiency on the function of the multiprotein-channel complex does not 
depend on an overall reduction of respiratory chain activity and thereby altered cell 
behavior. 
Although no conclusive results could be shown for the localization of PHB1 to the slit 
diaphragm three arguments suggest that probably both, PHB1 and PHB2, act 
together at the slit diaphragm: first, previous work published from different groups 
showed that PHB1 and PHB2 exist in multimeric ring structures and stabilize each 
other [28,49,50]; second, PHB1 was shown to co-precipitate with podocin in 
overexpression; finally, phb-1-deficiency led to the same decrease in touch sensitivity 
as phb-2-deficiency.  
A possible mode of action of PHB2 and probably PHB1 on the functionality of the 
protein-lipid supercomplex could be a stabilizing effect. Thereby, loss of PHB2 could 
lead to increased stretch-evoked activation of the ion-channel protein transient 
receptor potential cation channel 6 (TRPC6) - a component of slit diaphragm 
supercomplex [14,15] - as suggested for podocin deficiencies as well [24,138]. 
The finding that PHB2 localizes to the slit diaphragm protein-lipid supercomplex is 
further emphasized by results from other groups, showing that prohibitins can be 
detected in detergent-resistant lipid rafts [30,122,139] as shown for podocin as well 
[140]. These specialized membrane compartments are absent in mitochondria [139], 
further supporting a function of prohibitins in slit diaphragm protein-lipid 
supercomplexes at the plasma membrane. The identification of PHB2 as a second 
SPFH domain-containing protein at the slit diaphragm changes the current view of 
our understanding of a podocin-multimeric-complex, which may also be comprised of 
several SPFH domain-containing proteins.  
 
7.1.3 Phb2-deficiency in podocytes affects mitochondrial and 
non-mitochondrial functions 
Several lines of evidence point into the direction of not only a mitochondrial but also 
an extramitochondrial phenotype of Phb2pko mice. As discussed in section 7.1.1 
Phb2pko mice rapidly developed a severe phenotype which resembled that of other 
slit diaphragm protein-deficient mice. Furthermore, PHB2 localized not only to 
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mitochondria, but also to the slit diaphragm complex in mammals as well as to the 
highly similar multiprotein-channel complex in C. elegans (see section 7.1.2). 
Previous reports showed that Phb2-deficient cells are more susceptible to intrinsic 
apoptotic stimuli in vitro and in vivo [53,69,121,122]. A possible mechanism for the 
increased levels of proteinuria could be that podocytes of Phb2pko mice show either 
increased levels of mitochondria-induced apoptosis and/or detachment from the 
underlying GBM, consequently leading to cell loss. Interestingly, no increased 
caspase-3 cleavage was detected in three weeks old Phb2pko animals despite high 
albuminuric levels arguing against apoptosis as the primary mechanisms for 
podocyte damage at this time point. However, podocyte detachment from the GBM 
can also occur in the absence of apoptosis [141]. To investigate this, the overall 
podocyte cell number was assessed by counting WT-1-positive cells in paraffin 
sections, but no changes were detected in Phb2pko compared to Phb2fl/fl mice. 
Therefore, there is no evidence for the hypothesis that either increased apoptosis or 
early podocyte detachment account for the loss of podocyte function and initial 
development of albuminuria in Phb2pko mice. 
However, Phb2-deficient podocytes clearly show a mitochondria-related phenotype in 
addition as seen by the detection of disorganized and swollen mitochondria cristae 
structures within the cells of Phb2pko mice. Since the respiratory chain is localized 
within the cristae structures and has been shown to rely on prohibitins it can be 
speculated that the morphological changes could decrease respiratory chain activity 
and increase levels of reactive oxygen species (ROS). This would modulate cell 
metabolism by oxidation of e.g. proteins, lipids and DNA and also influence cell 
viability. Interestingly, various studies on this topic revealed opposing results. On the 
one hand, loss of prohibitins has been shown to increase ROS production by 
inhibition of the respiratory chain in e.g. human endothelial cells in vitro [142] and 
human epithelial colorectal adenocarcinoma cells in vitro [143] as well as 3T3-L1 
mouse embryonic fibroblast in vitro [144]. On the other hand, no or only a late impact 
on respiratory chain activity was seen in studies on prohibitin-deficient mouse 
epidermal progenitor/stem cells in vivo [121], mouse embryonic fibroblasts in vitro 
[53] and mouse neurons in the forebrain in vivo [69]. Possible reasons for these 
contrary results could either be cell type-specific differences in the impact of 
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prohibitin depletion on resipiratory chain activity and consequently ROS production or 
variable experimental settings.  
Mitochondrial dynamics are essential for a cell and mutations in genes that are 
important for fusion and fission events can lead to neurodegeneration [145–147]. The 
dynamic nature of the mitochondrial network is needed as a quality control and to 
mitigate the effect of damaged mitochondria. On the one hand, fusion allows 
redistribution of damaged content between intact and dysfunctional mitochondria, 
thereby maintaining the integrity of the whole network. On the other hand, fission 
ensures the effective elimination of damaged mitochondria by mitophagy, thus 
protecting the cell from mitochondria-induced apoptosis [148]. OPA1 is the central 
regulator of fusion at the inner mitochondrial membrane [149,150] and enhanced 
processing of OPA1 to shorter isoforms induces mitochondrial fragmentation [65]. 
Loss of PHB2 leads to unbalanced cleavage of OPA1 and subsequently fusion 
defects as seen by disorganized and swollen mitochondrial cristae structures [53].  
Several studies have reported morphological changes of mitochondria with disturbed 
cristae structures in podocytes of a FSGS mouse and rat model [151,152] as well as 
FSGS patients [153–155]. But whether the disruption of the mitochondrial network 
plays a role in the development of glomerulosclerosis or if it is a secondary effect of 
podocyte damage still remains to be elucidated. 
 
7.2 PHB2 is linked to the regulation of cell metabolism 
7.2.1 Phb2-deficiency influences metabolic signaling via the insulin and 
IGF-1 receptor 
Previous work from Artal-Sanz et al. [70] and Schleit et al. [71] suggests a role of 
PHB2 in cell metabolism via insulin/mTOR signaling. In worms, loss of PHB2 
decreased survival, but increased lifespan of already long-lived daf-2 mutant worms 
[70]. In yeast, Phb2-deficiency activated the mitochondrial untranslated protein 
response (mtUPR), which is associated with reduced lifespan. This effect could be 
inhibited by dietary restriction, thereby reducing the mtUPR [71]. Taken together, 
these findings raised the hypothesis of a potential link of PHB2 and insulin/mTORC1 
signaling in mammalian organ systems. In contrast to nematodes, the insulin receptor 
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and the IGF-1 receptor mediate the action of growth factors on cell metabolism in 
mammals. Both have been shown to be expressed in podocytes [156–159]. 
To investigate if the deleterious effect of the podocyte-specific Phb2-deficiency is 
dependent on signaling via the insulin receptor and/or the IGF-1 receptor pathway, 
podocyte-specific double knockout mice were generated that either lacked PHB2 and 
the insulin receptor (Phb2pko/Insrpko mice) or PHB2 and the IGF-1 receptor 
(Phb2pko/Igf1rpko mice). Assessing survival of these animals revealed a beneficial 
effect on lifespan in Phb2pko/Insrpko but not Phb2pko/Igf1rpko mice compared to 
Phb2pko mice. All mice rapidly developed massive albuminuria and no differences 
were observed between the different genotypes. These results indicate that although 
filtering properties are impaired in Phb2pko/Insrpko the damage of podocytes which 
probably leads to renal failure in the end is delayed compared to Phb2pko mice. 
Insulin and IGF-1 cannot only bind and activate their specific receptor, but insulin can 
also bind to the IGF-1 receptor and IGF—1 to the insulin receptor with differing 
affinities [132]. Loss of the insulin receptor under standard plasma insulin and IGF-1 
levels might then lead to increased activation of the IGF-1 receptor. To test for an 
additional beneficial effect after loss of of the IGF-1 receptor, triple podocyte-specific 
knockout mice lacking PHB2, the insulin receptor and IGF-1 receptor 
(Phb2pko/Insrpko/Igf1rpko mice) were generated and survival was monitored. Deletion of 
just one Igf1r allel in addition to homozygous Phb2- and Insr-deletions did not show 
any overt effect on survival compared to Phb2pko/Insrpko mice (50% mortality rate of 
Phb2pko/Insrpko/Igf1rhet mice at day 37, mean lifespan of ~36 days vs. 50% mortality 
rate of Phb2pko/Insrpko mice at day 38 and a mean lifespan of ~38 days). Intriguingly, 
Phb2pko/Insrpko/Igf1rpko mice showed a 50% mortality rate at day 43 and a mean 
lifespan of ~86 days. However, the survival rate of Phb2pko/Insrpko/Igf1rpko mice was 
extremely diverse. While some mice did not die by the end of the study others 
showed a medium survival and some died in the same time frame as Phb2pko mice. 
These differences could be caused by insufficient and differing Cre activity in this 
triple knockout mouse model. Arguing against an ineffective Cre recombinase, all 
Phb2pko/Insrpko/Igf1rpko mice developed massive albuminuria which was present until 
they died. Since double knockouts of the insulin and IGF-1 receptor alone do not 
show any overt albuminuria until at least 8 weeks after birth (data not shown), the 
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development of albuminuria in the triple knockout mouse model is probably due to 
the loss of PHB2 and cannot be rescued by interfering with metabolic signaling. 
 
7.2.2 Dysregulated mTOR signaling leads to glomerular diseases 
The benefical effect of the loss of insulin signaling in Phb2pko mice raised the 
question whether activation of the downstream mediator mTORC1 is involved in 
podocyte damage in this model. 
Interestingly, staining for phosphorylated S6 ribosomal protein - a downstream target 
of mTORC1 signaling widely used to assess the activation status of 
mTORC1 - revealed enhanced phosphorylation of S6 ribosomal protein not only in 
Phb2-depleted podocytes in vitro but also in vivo. Hyperactivation of mTORC1 has 
been shown to cause glomerular diseases in mice and humans before 
[95,104,160,161]. For example, diabetic mice show increased mTORC1 activation 
but benefit from podocyte-specific mTORC1 suppression and are less proteinuric 
under mTORC1 inhibition. Furthermore, constitutive podocyte-specific activation of 
mTORC1 by ablation of the upstream negative regulator TSC1 results in the 
development of a glomerular disease similar to diabetic nephropathy including 
proteinuria. Treatment with rapamycin ameliorated proteinuria in that study [104]. 
Rats treated with puromycin aminonucleoside (PAN) to induce nephrosis show 
hyperactivation of mTORC1 as well and can be protected from proteinuria by 
treatment with rapamycin or a rapamycin derivate [160,161].  
Compared to Phb2pko mice the progression of the disease in both, PAN-induced 
nephrosis rats and Tsc1-knockout mice, is much slower and animal models with 
hyperactive mTORC1 rather developed features of diabetic nephropathy with GBM 
thickening and mesangial expansion while Phb2pko mice presented with a FSGS-like 
pathology [104,160,161]. Additionally, Phb2pko mice died around 31-37 days after 
birth while e.g. Tsc1-knockout mice survived at least eight weeks when they were 
analyzed in the less susceptible C57BL/6 background which was also used for the 
Phb2pko study. Rapamycin treatment before onset of the disease suppressed the 
development of proteinuria in Tsc1-knockout mice completely [104] but shows no 
effect on albuminuria in Phb2pko mice. Therefore, it can be speculated that the 
hyperactivation of mTORC1 is not the initial cause of albuminuria and 
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glomerulosclerosis in Phb2pko mice but rather the consequence of PHB2 depletion at 
the slit diaphragm as discussed under 7.1.2.  
Intriguingly, lifespan of Phb2pko mice is clearly increased under rapamycin treatment, 
suggesting that the fast progression of the disease and severity of podocyte damage 
in this model depends on mTORC1 activity. This hypothesis is in line with the studies 
discussed here, illustrating that dysregulation of mTOR signaling in podocytes 
causes glomerular diseases [95,104,160,161]. Gödel et al. [95] raised the hypothesis 
that under pathologic conditions like diabetic nephropathy in patients mTOR is 
activated to counteract the metabolic changes in the disease. But despite of 
short-term beneficial effects of the increased mTORC1 activation this dysregulation 
ultimately facilitates disease progression. Clearly, this could hold true for Phb2pko 
mice as well, but the underlying molecular mechanism needs to be investigated 
further. One hypothesis could be that the development of any glomerular disease 
sensitizes the same pathway which ultimately leads to activation of mTOR as a 
common final effector pathway. Another hypothesis could be that mTOR activation is 
mediated via distinct pathways specific for the underlying podocyte defect. So far, 
hyperactivation of mTORC1 has only been shown in diabetic nephropathy 
[95,104,161] and glomerulonephritis [160,162] models as well as glomerulosclerosis 
arising from Phb2-deficiency. To be able to draw any conclusive result more 
glomerular disease models need to be analyzed for hyperactivity of mTORC1 and 
mechanisms of activation. Clearly, so far it cannot be ruled out that mTOR activation 
could also be a secondary effect caused by the development of albuminuria as a 
metabolic switch meant to counteract the disease. But there is no actual data 
available showing that albuminuria per se causes mTOR activation, neither in this 
model nor in any other published report on mTOR activation and proteinuria. 
Phb2pko mice treated with rapamycin showed a 50% mortality rate at day 42 and a 
mean lifespan of ~44 days whereas Phb2pko/Insrpko/Igf1rpko mice showed a 50% 
mortality rate at day 43 and a mean lifespan of ~86 days. This high increase in mean 
lifespan of Phb2pko/Insrpko/Igf1rpko mice can be explained by the fact that some 
Phb2pko/Insrpko/Igf1rpko mice did not die by renal failure in the end but survived until 
the end of the study. In contrast, in the rapamycin-treated Phb2pko study group only 
one mouse survived until the end of the study. This could be on the one hand due to 
unequal numbers of mice that were analyzed. The rapamycin-treated Phb2pko study 
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group included only 8 mice while the Phb2pko/Insrpko/Igf1rpko study group contained 19 
individual subjects. On the other hand, this could also be explained by the fact that 
the effect of an intraperitonally administered drug might not be as pronounced as a 
knockout model. For this study, it is not known which concentration of rapamycin 
reaches the podocyte in the end and for how long the rapamycin concentration is 
high enough to exert its beneficial effects. In this regard, the triple knockout mouse 
might serve as a better model to study metabolic effects in Phb2-deficient mice. 
 
7.2.3 Hypothesis: Loss of PHB2 sensitizes the insulin receptor 
Investigation of the molecular mechanism how loss of PHB2 leads to increased 
mTORC1 activity in vitro and in vivo might provide novel insights into the crosstalk of 
mitochondria and insulin/mTOR signaling in health and disease. This thesis work 
suggests that the effect of Phb2-deficiency on mTOR activity is mediated via 
activation of the insulin and IGF-1 receptor and that dysregulated signaling is 
detrimental to cell metabolism and survival as reflected by slowing progression of 
glomerular disease with rapamycin treatment or knockout of the insulin receptor and 
IGF-1 receptor. 
A possible mechanism could be that loss of mitochondrially localized PHB2 leads to 
the production of reactive oxygen species (ROS) including H2O2 in podocytes. These 
effect has already been shown for several other but not all cell types in vitro and in 
vivo [53,69,121,142–144]. A mild but not high increase in ROS production has been 
suggested to enhance insulin sensitivity by two mechanisms: first, facilitation of the 
insulin-stimulated tyrosine autophosphorylation of the insulin receptor; second, 
oxidation and inhibition of PTEN, a suppressor of the insulin/IGF-1 receptor 
downstream target AKT [163–165]. Furthermore, oxidative stress can also induce 
activation of the IGF-1 receptor [166]. Therefore, an increase in ROS production 
could enhance insulin/IGF-1 signaling and activate mTORC1. The study in worms 
showed that Phb2-deficiency leads to increased mitochondrial content [70]. This 
ROS-induced enhanced insulin sensitivity model could provide two explanations for 
this finding. Firstly, the activation of the mTORC1 pathway could result in the 
inhibition of autophagy [167], thereby preventing the breakdown of structurally 
disorganized and maybe dysfunctional mitochondria further promoting disease 
progression. Secondly, enhanced activation of insulin/IGF-1 signaling leads to 
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phosphorylation of the transcription factor FOXO1 thereby preventing FOXO1 from 
translocation into the nucleus [168–170]. FOXO1 is amongst others necessary for the 
transcription of a gene that encodes for an enzyme leading to heme depletion [171]. 
Heme is an important co-factor for the OXPHOS system. Loss of heme results in 
reduced electron transfer from e.g. NADH and FADH2 and alters the ratio of 
NAD+/NADH which is a sensor for mitochondrial biogenesis. When FOXO1 
translocates to the nucleus the NAD+/NADH ratio decreases and blocks 
mitochondrial biogenesis [171]. Lack of PHB2 and subsequent activation of the 
insulin/IGF-1 signaling pathway retain FOXO1 in the cytoplasm and allow 
mitochondrial biogenesis leading to more ROS production and again enhanced 
insulin sensitivity. This would foster a vicious circle from which escape is possible by 
directly interfering with signaling on the level of the insulin receptor and IGF-1 
receptor. However, this does not explain the benefical effect of mTORC1 inhibition in 
Phb2pko mice. But with regard to the function of active mTORC1 in promoting gene 
transcription and protein translation, inhibition of mTORC1 could deplete the cell of 
components necessary for mitochondrial biogenesis leading to a similar effect as loss 
of the insulin and IGF-1 receptor. 
. 
 
Figure 17. Hypothesis: Loss of PHB2 sensitizes the insulin receptor 
Loss of PHB2 in mitochondria could increase ROS production which on the one hand 
might lead to activation of the insulin and IGF-1 receptor and thereby signaling via 
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AKT. On the other hand, increased ROS could inhibit PTEN which under normal 
conditions would inhibit AKT. AKT activation would lead not only to mTORC1 
activation but also to the inhibition of FOXO1-phosphorylation, resulting in heme 
depletion and a decreasing NAD+/NADH ratio. This could promote mitochondrial 
biogenesis, leading to the accumulation of more Phb2-deficient mitochondria. 
Increased mitochondrial biogenesis could be further supported by elevated 
transcription and translation processes via mTORC1 activation and the inhibition of 
autophagy by mTORC1 may further promote accumulation of the dysfunctional 
mitochondria. (ETC = electron transport chain; ROS = reactive oxygen species) 
 
Clearly, the hypothesis that increased ROS production from Phb2-deficient 
podocytes leads to enhanced insulin sensitivity needs further testing. Of course, it is 
very well conceivable that other factors than ROS activate the insulin and IGF-1 
receptor in PHB2-depleted conditions to mediate hyperactivation of mTORC1 and the 
potentially deleterious effects of this dysregulation. 
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8 Conclusion 
By using different techniques like immunofluorescence, immunogold-labeling and 
co-immunoprecipitation PHB2 was not only shown to localize to mitochondria but 
also to the podocyte slit diaphragm protein-lipid supercomplex. Podocyte-specific 
Phb2-deficient mice (Phb2pko mice) developed progressive albuminuria and 
glomerulosclerosis and died prematurely from renail failure, thereby resembling 
phenotypes of mice lacking other slit diaphragm protein knockout mice. Experiments 
in the nematode C. elegans further supported the localization of PHB2 to the 
protein-lipid supercomplex and revealed an essential impact of PHB2 on the 
functionality of this mechanosensitive complex in worms. Collectively, this thesis 
works suggests an extramitochondrial function of PHB2 at the slit diaphragm of 
podocytes. 
Furthermore, inhibition of mTORC1 signaling by either rapamycin-treatment of 
podocyte-specific Phb2-deficient mice or loss of the insulin receptor and IGF-1 
receptor prolonged lifespan of the Phb2pko mice by a so far unknown mechanism. 
Interestingly, albuminuria developed in these animals despite suppression of 
mTORC1 activity. In conclusion, this indicates that the development of albuminuria 
could be the result of the loss of function of PHB2 at the slit diaphragm but the fast 
progression of the glomerular disease depends on hyperactive mTORC1 after 
PHB2-depletion. 
 
Figure 18. Why does loss of PHB2 lead to glomerular disease? 
Loss of PHB2 ultimately leads to glomerular disease via two probably distinct 
pathways. On the one hand, PHB2-depletion results in foot process effacement 
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because of its localization to the slit diaphragm, which results in loss of filter function 
(resulting in albuminuria). On the other hand, Phb2-deficiency leads to mitochondria 
dysfunction which enhances mTOR activation, resulting in a detrimental metabolic 
switch in podocytes (leading to podocyte loss). These two pathways together underlie 
the severe glomerular disease seen in Phb2pko mice. 
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